Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody

ABSTRACT

Described is the sequential administration of first a Treg depleting antibody mole-cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De-scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.

This application is a continuation of U.S. application Ser. No.16/633,740, filed on Jan. 24, 2020, which is a national phaseapplication under 35 U.S.C. § 371 of International Application No.PCT/EP2018/070359, filed Jul. 26, 2018, which claims benefit of priorityto United Kingdom Patent Application No. 1712032.0, filed Jul. 26, 2017.The entire contents of U.S. Ser. No. 16/330,740 and InternationalApplication No. PCT/EP2018/070359 are hereby incorporated by reference.

This application contains a Sequence Listing XML, which has beensubmitted electronically and is hereby incorporated by reference in itsentirety. Said XML Sequence Listing, created on Aug. 10, 2022, is namedEPCLP0070USC1.xml and is 180,422 bytes in size.

FIELD OF THE INVENTION

The present invention relates to sequential administration of first aTreg depleting antibody molecule and then an immunostimulatory antibodymolecule for use in the treatment of cancer. The invention also relatesto novel antibodies for use in such treatment, including novel anti-4-1BB antibodies and novel anti-OX40 antibodies.

BACKGROUND OF THE INVENTION

Promising clinical results with immunomodulatory mAb have revived thebelief that the immune system holds the key to controlling cancer. Theclassification of these mAb into checkpoint blockers (antagonists) oractivators of co-stimulatory molecules (agonists) has recently come intoquestion with the finding that examples of both types may combat tumoursthrough activatory FcγR engagement and depletion of suppressiveregulatory T cells (Treg). In contrast to these findings, anti-CD40 mAbdepend on inhibitory FcγR cross-linking for agonistic immunestimulation. Therefore whilst immunomodulatory mAb offer considerablepromise for cancer immunotherapy the effector mechanisms employed byvarious mAb, and consequently their optimal application, remain to bedefined.

Immunomodulatory mAb, such as ipilimumab (anti-CTLA4), anti-PD-1/PD-L1and anti-CD40 have shown positive outcomes when trialled indifficult-to-treat malignancies, albeit in a minority of patients (1-4).These promising results have helped to reinvigorate the belief that theimmune system can hold the key to controlling cancer. These mAb weregenerated to target key molecular regulators on T cells or APC and toboost anti-cancer immunity through blockade of inhibitory signals(checkpoint blockers) or delivery of co-stimulatory signals (agonists).Recently this binary classification has come into question when thetherapeutic activity of anti-CTLA4, anti-GITR and anti-OX40, which alltarget T cells, was found to involve deletion of suppressive CD4+Tregulatory cells dependent on co-engagement of activatory FcγRs (5-7).The activity of the agonist APC-targeting anti-CD40 mAb, in contrast,requires co-engagement of the inhibitory FcγR to facilitate effectivemAb cross-linking, which is necessary for CD40 signalling and immunestimulation (8-10). Therefore, whilst immunomodulatory mAb offerconsiderable promise for cancer immunotherapy, the mechanisms employeddepend on both the Fab and Fc regions of the mAb in ways which areill-defined and which may depend on the cell type being targeted.Understanding the relative importance of T_(reg) depletion versus directimmune-stimulation will be vital to the development and successfultranslation of immunomodulatory mAb to patients.

SUMMARY OF THE INVENTION

The present invention is based on research demonstrating that anti-4-1BB mAb can employ either direct immune-stimulation or T_(reg) depletionin solid tumours, with the primary mechanism dependant on antibodyisotype and FcγR availability. Importantly, depletion andimmunostimulation appear to be competitive mechanisms, likely limited byrestrictions on FcγR engagement. The research leading to the presentinvention has further shown that sequential administration ofisotype-disparate anti-4-1 BB mAbs or isotype-optimal anti-4-1 BB mAbfollowed by anti-PD-1 mAb to initially delete Treg and then stimulateCD8 T cells leads to augmented responses, resulting in enhanced therapyand improved outcome. Furthermore, the inventors engineered a depletinganti-4-1 BB mIgG2a with human IgG2 hinge region ‘B’ (mIgG2a/h2B) toprovide FcγR independent agonism and demonstrate that this single mAb iscapable of harnessing both mechanisms to deliver enhanced therapy.

This was then broadened by demonstration that Treg depletion followed byimmunostimulation can be achieved with further antibodies in addition toanti-4-1 BB mAb, namely a Treg depleting antibody molecule, such as anantibody molecules binding specifically to target belonging to thetumour necrosis factor receptor superfamily (TNFRSF), for example a Tregdepleting anti-4-1 BB antibody or a Treg depleting anti-OX40 antibody,in combination with an immunostimulatory antibody molecule, such as animmunostimulatory anti-4-1 BB antibody, an immunostimulatory anti-OX40antibody or an immune activatory PD-1 blocking antibody, wherein theorder of administration is of importance to achieve the desired effect.The research also lead to the development of novel anti-4-1 BBantibodies and novel anti-OX40 antibodies.

Thus, the present invention relates to a Treg depleting antibodymolecule for use in the treatment of cancer wherein the Treg depletingantibody molecule is administered sequentially with an immunostimulatoryantibody molecule with the Treg depleting antibody molecule beingadministered prior to administration of the immunostimulatory antibodymolecule.

The present invention further relates to a method of treating a cancerin a subject, said treatment comprising administration of a Tregdepleting antibody molecule followed sequentially by administration ofan immunostimulatory antibody molecule.

The present invention further relates to an anti-4-1BB antibody moleculeselected from the group consisting of antibody molecules comprising oneor more of the CDRs selected from SEQ. ID. NOs: 1-6, 9-14, 17-22, 25-30,33-38, 41-46, 49-54, 57-62, 65-70, 153-158 and 163-168. “One or more”means in this context that the antibody molecule comprises 1, 2, 3, 4, 5or 6 of the indicated sequences, i.e. 1-6 of the indicated sequences.Thus, the anti-4-1 BB antibody molecule may comprise 1-6 of the CDRsselected from SEQ. ID. NOs: 1-6; 1-6 of the CDRs selected from SEQ. ID.NOs: 9-14; 1-6 of the CDRs selected from SEQ. ID. NOs: 17-22; 1-6 of theCDRs selected from SEQ. ID. NOs: 25-30; 1-6 of the CDRs selected fromSEQ. ID. NOs: 33-38; 1-6 of the CDRs selected from SEQ. ID. NOs: 41-46;1-6 of the CDRs selected from SEQ. ID. NOs: 49-54; 1-6 of the CDRsselected from SEQ. ID. NOs: 57-62; 1-6 of the CDRs selected from SEQ.ID. NOs: 65-70; 1-6 of the CDRs selected from SEQ. ID. NOs: 153-158; or1-6 of the CDRs selected from SEQ. ID. NOs: 163-168.

The present invention further relates to nucleotide acids encoding theabove anti-4-1 BB antibody molecules.

The present invention further relates to an anti-OX40 antibody moleculeselected from the group consisting of antibody molecule comprising oneor more of the CDRs selected from SEQ. ID. NOs: 73-78, 81-86, 89-94,97-102, 105-110, SEQ. ID. NOs: 113-118, SEQ. ID. NOs: 121-126, SEQ. ID.NOs: 129-134, SEQ. ID. NOs: 137-142, SEQ. ID. NOs: 145-150, and SEQ. ID.NOs: 171-176. Again “one or more” means in this context that theantibody molecule comprises 1, 2, 3, 4, 5 or 6 of the indicatedsequences, i.e. 1-6 of the indicated sequences. Thus, the anti-OX40antibody molecule may comprise 1-6 of the CDRs selected from SEQ. ID.NOs: 73-78; 1-6 of the CDRs selected from SEQ. ID. NOs: 81-86; 1-6 ofthe CDRs selected from SEQ. ID. NOs: 89-94; 1-6 of the CDRs selectedfrom SEQ. ID. NOs: 97-102; 1-6 of the CDRs selected from SEQ. ID. NOs:105-110; 1-6 of the CDRs selected from SEQ. ID. NOs: 113-118; 1-6 of theCDRs selected from SEQ. ID. NOs: 121-126; 1-6 of the CDRs selected fromSEQ. ID. NOs: 129-134; 1-6 of the CDRs selected from SEQ. ID. NOs:137-142; 1-6 of the CDRs selected from SEQ. ID. NOs: 145-150, or 1-6 ofthe CDRs selected from SEQ. ID. NOs: 171-176.

The present invention further relates to vectors comprising the abovenucleotide acids.

The present invention further relates to host cells comprising the abovenucleotide acids and/or the above vectors.

DETAILED DESCRIPTION OF THE INVENTION

Regulatory T cells, Treg cells, Tregs or T_(regs), (formerly known assuppressor T cells, sometimes also called suppressive regulatory Tcells), are a subpopulation of T cells which are capable of suppressingother immune cells in normal and pathological immune settings.

By depletion of Tregs, or Treg depletion, we refer herein to depletion,deletion or elimination of Tregs through physical clearance of cells. Inparticular, we refer to depletion of intratumoural Tregs.

Effector T cells are T cells or T lymphocytes that in response tostimulus activate, attack or destroy antigen-expressing cells in anantigen:MHC:TCR-restricted manner. Effector T cells may control cancerand eradicate tumor cells directly (cytotoxic T cells), or indirectly (THelper cells) through activation of other immune cells.

Antibodies are well known to those skilled in the art of immunology andmolecular biology. Typically, an antibody comprises two heavy (H) chainsand two light (L) chains. Herein, we sometimes refer to this completeantibody molecule as a full-size or full-length antibody. The antibody'sheavy chain comprises one variable domain (VH) and three constantdomains (CH1, CH2 and CH3), and the antibody's molecule light chaincomprises one variable domain (VL) and one constant domain (CL). Thevariable domains (sometimes collectively referred to as the Fv region)bind to the antibody's target, or antigen. Each variable domaincomprises three loops, referred to as complementary determining regions(CDRs), which are responsible for target binding. The constant domainsare not involved directly in binding an antibody to an antigen, butexhibit various effector functions. Depending on the amino acid sequenceof the constant region of their heavy chains, antibodies orimmunoglobulins can be assigned to different classes. There are fivemajor classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and inhumans several of these are further divided into subclasses (isotypes),e.g., IgG1, IgG2, IgG3, and IgG4; IgA1 and IgA2. Another part of anantibody is the Fc domain (otherwise known as the fragmentcrystallisable domain), which comprises two of the constant domains ofeach of the antibody's heavy chains. The Fc domain is responsible forinteractions between the antibody and Fc receptor.

Fc receptors are membrane proteins which are often found on the cellsurface of cells of the immune system (i.e. Fc receptors are found onthe target cell membrane—otherwise known as the plasma membrane orcytoplasmic membrane). The role of Fc receptors is to bind antibodiesvia the Fc domain, and to internalize the antibody into the cell. In theimmune system, this can result in antibody-mediated phagocytosis andantibody-dependent cell-mediated cytotoxicity.

The term antibody molecule, as used herein, encompasses full-length orfull-size antibodies as well as functional fragments of full lengthantibodies and derivatives of such antibody molecules.

Functional fragments of a full-size antibody have the same antigenbinding characteristics as the corresponding full-size antibody andinclude either the same variable domains (i.e. the VH and VL sequences)and/or the same CDR sequences as the corresponding full-size antibody.That the functional fragment has the same antigen bindingcharacteristics as the corresponding full-size antibody means that itbinds to the same epitope on the target as the full-size antibody. Sucha functional fragment may correspond to the Fv part of a full-sizeantibody. Alternatively, such a fragment may be a Fab, also denotedF(ab), which is a monovalent antigen-binding fragment that does notcontain a Fc part, or a F(ab′)2, which is an divalent antigen-bindingfragment that contains two antigen-binding Fab parts linked together bydisulfide bonds or a F(ab′), i.e. a monovalent-variant of a F(ab′)2.Such a fragment may also be single chain variable fragment (scFv).

A functional fragment does not always contain all six CDRs of acorresponding full-size antibody. It is appreciated that moleculescontaining three or fewer CDR regions (in some cases, even just a singleCDR or a part thereof) are capable of retaining the antigen-bindingactivity of the antibody from which the CDR(s) are derived. For example,in Gao et al., 1994, J. Biol. Chem., 269: 32389-93 it is described thata whole VL chain (including all three CDRs) has a high affinity for itssubstrate.

Molecules containing two CDR regions are described, for example, byVaughan & Sollazzo 2001, Combinatorial Chemistry & High ThroughputScreening, 4: 417-430. On H2 CDR hypervariable regions interspersedwithin framework regions is described. The minibody is described asbeing capable of binding to a target. Pessi et al., 1993, Nature, 362:367-9 and Bianchi et al., 1994, J. Mol. Biol., 236: 649-59 arereferenced by Vaughan & Sollazzo and describe the H1 and H2 minibody andits properties in more detail. In Qiu et al., 2007, NatureBiotechnology, 25:921-9 it is demonstrated that a molecule consisting oftwo linked CDRs are capable of binding antigen. Quiocho 1993, Nature,362: 293-4 provides a summary of “minibody” technology. Ladner 2007,Nature Biotechnology, 25:875-7 comments that molecules containing twoCDRs are capable of retaining antigen-binding activity.

Antibody molecules containing a single CDR region are described, forexample, in Laune et al., 1997, JBC, 272: 30937-44, in which it isdemonstrated that a range of hexapeptides derived from a CDR displayantigen-binding activity and it is noted that synthetic peptides of acomplete, single, CDR display strong binding activity. In Monnet et al.,1999, JBC, 274: 3789-96 it is shown that a range of 12-mer peptides andassociated framework regions have antigen-binding activity and it iscommented on that a CDR3-like peptide alone is capable of bindingantigen. In Heap et al., 2005, J. Gen. Virol., 86: 1791-1800 it isreported that a “micro-antibody” (a molecule containing a single CDR) iscapable of binding antigen and it is shown that a cyclic peptide from ananti-HIV antibody has antigen-binding activity and function. In Nicaiseet al., 2004, Protein Science, 13:1882-91 it is shown that a single CDRcan confer antigen-binding activity and affinity for its lysozymeantigen.

Thus, antibody molecules having five, four, three or fewer CDRs arecapable of retaining the antigen binding properties of the full-lengthantibodies from which they are derived.

The antibody molecule may also be a derivative of a full-length antibodyor a fragment of such an antibody. The derivative has the same antigenbinding characteristics as the corresponding full-size antibody in thesense that it binds to the same epitope on the target as the full-sizeantibody.

Thus, by the term “antibody molecule”, as used herein, we include alltypes of antibody molecules and functional fragments thereof andderivatives thereof, including: monoclonal antibodies, polyclonalantibodies, synthetic antibodies, recombinantly produced antibodies,multi-specific antibodies, bi-specific antibodies, human antibodies,humanized antibodies, chimeric antibodies, single chain antibodies,single-chain Fvs (scFv), Fab fragments, F(ab′)2 fragments, F(ab′)fragments, disulfide-linked Fvs (sdFv), antibody heavy chains, antibodylight chains, homo-dimers of antibody heavy chains, homo-dimers ofantibody light chains, heterodimers of antibody heavy chains,heterodimers of antibody light chains, antigen binding functionalfragments of such homo- and heterodimers.

Further, the term “antibody molecule”, as used herein, includes allclasses of antibody molecules and functional fragments, including: IgG,IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgD, and IgE.

In some embodiments, the antibody is a human IgG1. The skilled person isaware that the mouse IgG2a and human IgG1 productively engage withactivatory Fc gamma receptors, and share the ability to activatedeletion of target cells through activation of activatory Fc gammareceptor bearing immune cells (e.g. macrophages and NK cells) by e.g.ADCP and ADCC. As such, whereas the mouse IgG2a is the preferred isotypefor deletion in the mouse, human IgG1 is a preferred isotype fordeletion in human. Conversely, it is known that optimal co-stimulationof TNFR superfamily agonist receptors e.g. 4-1 BB, ox40, TNFRII, CD40depends on antibody engagement of the inhibitory FcγRII. In the mousethe IgG1 isotype, which binds preferentially to inhibitory Fc gammareceptor (FcγRIIB) and only weakly to activatory Fc gamma receptors, isknown to be optimal for costimulatory activity of TNFR-superfamilytargeting mAb. While no direct equivalent of the mouse IgG1 isotype hasbeen described in man, antibodies may be engineered to show a similarlyenhanced binding to inhibitory over activatory human Fc gamma receptors.Such engineered TNFR-superfamily targeting antibodies also have improvedco-stimulatory activity in vivo, in transgenic mice engineered toexpress human activatory and inhibitory Fc gamma receptors (49).

As outlined above, different types and forms of antibody molecules areincluded in the invention, and would be known to the person skilled inimmunology. It is well known that antibodies used for therapeuticpurposes are often modified with additional components which modify theproperties of the antibody molecule.

Accordingly, we include that an antibody molecule of the invention or anantibody molecule used in accordance with the invention (for example, amonoclonal antibody molecule, and/or polyclonal antibody molecule,and/or bi-specific antibody molecule) comprises a detectable moietyand/or a cytotoxic moiety.

By “detectable moiety”, we include one or more from the group comprisingof: an enzyme; a radioactive atom; a fluorescent moiety; achemiluminescent moiety; a bioluminescent moiety. The detectable moietyallows the antibody molecule to be visualised in vitro, and/or in vivo,and/or ex vivo.

By “cytotoxic moiety”, we include a radioactive moiety, and/or enzyme,wherein the enzyme is a caspase, and/or toxin, wherein the toxin is abacterial toxin or a venom; wherein the cytotoxic moiety is capable ofinducing cell lysis.

We further include that the antibody molecule may be in an isolated formand/or purified form, and/or may be PEGylated.

As discussed above, the CDRs of an antibody bind to the antibody target.The assignment of amino acids to each CDR described herein is inaccordance with the definitions according to Kabat E A et al. 1991, In“Sequences of Proteins of Immulogical Interest” Fifth Edition, NIHPublication No. 91-3242, pp xv-xvii.

As the skilled person would be aware, other methods also exist forassigning amino acids to each CDR. For example, the InternationalImMunoGeneTics information system (IMGT®) (http://www.imgt.org/ andLefranc and Lefranc “The Immunoglobulin FactsBook” published by AcademicPress, 2001).

In a further embodiment, the antibody molecule of the present inventionor used according to the invention is an antibody molecule that iscapable of competing with the specific antibodies provided herein, forexample antibody molecules comprising any of the amino acid sequencesset out in for example SEQ ID NOs: 1-152 for binding to the specifictarget. By “capable of competing for” we mean that the competingantibody is capable of inhibiting or otherwise interfering, at least inpart, with the binding of an antibody molecule as defined herein to thespecific target.

For example, such a competing antibody molecule may be capable ofinhibiting the binding of an antibody molecule described herein by atleast about 10%; for example at least about 20%, or at least about 30%,at least about 40%, at least about 50%, at least about 60%, at leastabout 70%, at least about 80%, at least about 90%, at least about 95%,at least about 100% and/or inhibiting the ability of the antibodydescribed herein to prevent or reduce binding to the specific target byat least about 10%; for example at least about 20%, at least about 30%,at least about 40%, at least about 50%, at least about 60%, at leastabout 70%, at least about 80%, at least about 90%, at least about 95%,or at least about 100%.

Competitive binding may be determined by methods well known to thoseskilled in the art, such as Enzyme-linked immunosorbent assay (ELISA).

ELISA assays can be used to evaluate epitope-modifying or blockingantibodies. Additional methods suitable for identifying competingantibodies are disclosed in Antibodies: A Laboratory Manual, Harlow &Lane, which is incorporated herein by reference (for example, see pages567 to 569, 574 to 576, 583 and 590 to 612, 1988, CSHL, NY, ISBN0-87969-314-2).

It is well known that an antibody specifically binds a defined targetmolecule or antigen. That is to say, the antibody preferentially andselectively binds its target and not a molecule which is not a target.

The targets of the antibodies according to the present invention, or ofthe antibodies used in accordance with the invention, are expressed onthe surface of cells, i.e. they are cell surface antigen, which wouldinclude an epitope (otherwise known in this context as a cell surfaceepitope) for the antibody. Cell surface antigen and epitope are termsthat would be readily understood by one skilled in immunology or cellbiology.

By “cell surface antigen”, we include that the cell surface antigen isexposed on the extracellular side of the cell membrane, but may only betransiently exposed on the extracellular side of the cell membrane. By“transiently exposed”, we include that the cell surface antigen may beinternalized into the cell, or released from the extracellular side ofthe cell membrane into the extracellular space. The cell surface antigenmay be released from the extracellular side of the cell membrane bycleavage, which may be mediated by a protease.

We also include that the cell surface antigen may be connected to thecell membrane, but may only be transiently associated with the cellmembrane. By “transiently associated”, we include that the cell surfaceantigen may be released from the extracellular side of the cell membraneinto the extracellular space. The cell surface antigen may be releasedfrom the extracellular side of the cell membrane by cleavage, which maybe mediated by a protease.

We further include that the cell surface antigen may be a peptide, or apolypeptide, or a carbohydrate, or an oligosaccharide chain, or a lipid;and/or an epitope that is present on a protein, or a glycoprotein, or alipoprotein.

Methods of assessing protein binding are known to the person skilled inbiochemistry and immunology. It would be appreciated by the skilledperson that those methods could be used to assess binding of an antibodyto a target and/or binding of the Fc domain of an antibody to an Fcreceptor; as well as the relative strength, or the specificity, or theinhibition, or prevention, or reduction in those interactions. Examplesof methods that may be used to assess protein binding are, for example,immunoassays, BIAcore, western blots, radioimmunoassay (RIA) andenzyme-linked immunosorbent assays (ELISAs) (See Fundamental ImmunologySecond Edition, Raven Press, New York at pages 332-336 (1989) for adiscussion regarding antibody specificity).

Accordingly, by “antibody molecule the specifically binds” or “targetspecific antibody molecule” we include that the antibody moleculespecifically binds a target but does not bind to non-target, or binds toa non-target more weakly (such as with a lower affinity) than thetarget.

We also include the meaning that the antibody specifically binds to thetarget at least two-fold more strongly, or at least five-fold morestrongly, or at least 10-fold more strongly, or at least 20-fold morestrongly, or at least 50-fold more strongly, or at least 100-fold morestrongly, or at least 200-fold more strongly, or at least 500-fold morestrongly, or at least than about 1000-fold more strongly than to anon-target.

Additionally, we include the meaning that the antibody specificallybinds to the target if it binds to the target with a K_(d) of at leastabout 10⁻¹ K_(d), or at least about 10⁻² K_(d), or at least about 10⁻³K_(d), or at least about 10⁻⁴ K_(d), or at least about 10⁻⁵ K_(d), or atleast about 10⁻⁶ K_(d), or at least about 10⁻⁷ K_(d), or at least about10⁻⁸ K_(d), or at least about 10⁻³ K_(d), or at least about 10⁻¹⁰ K_(d),or at least about 10⁻¹¹ K_(d), or at least about 10⁻¹² K_(d), or atleast about 10⁻¹³ K_(d), or at least about 10⁻¹⁴ K_(d), or at leastabout 10⁻¹⁵ K_(d).

As used herein, the term Treg depleting antibody refers to an antibodythat upon administration to a subject, such as a human, specificallybinds to a target expressed on the surface of Tregs, wherein thisbinding results in depletion of Tregs. Thus, a Treg depleting antibodyselected from antibodies binding specifically to target belonging to thetumour necrosis factor receptor superfamily (TNFRSF) is an antibody thatupon administration to a subject, such as a human, binds to a targetbelonging to the tumour necrosis factor receptor superfamily expressedon the surface of Tregs and wherein the binding results in depletion ofTregs. In some embodiments, the target belonging to the tumour necrosisfactor receptor superfamily is a target that is preferentially expressedon a tumour or in the tumour microenvironment.

In some embodiments, the Treg depleting antibody does not have anyimmunostimulatory effects in addition to the Treg depleting effects. Insome embodiments, the Treg depleting antibody also has animmunostimulatory effect, in addition to the Treg depleting effects; insuch embodiments the Treg depleting antibody has a sufficiently poorimmunostimulatory activity to allow for enhanced therapeutic activityfollowing sequential administration of a second immunostimulatoryantibody.

To decide whether an antibody is a Treg depleting antibody in themeaning of the present invention or not, it is possible to use an invitro antibody-dependent cellular cytotoxicity (ADCC) orantibody-dependent cellular phagocytosis (ADCP) assay.

An ADCC assay may be done by labelling target cells with calcein AM,followed by the addition of diluting concentrations of Ab. Target cellsis then cocultured with human PBMCs at a 50:1 E:T ratio for 4 h at 37°C. The plate is centrifuged at 400 3 g for 5 min to pellet the cells,and the supernatant is transferred to a white 96-well plate. Calceinrelease is measured using a Varioskan (Thermo Scientific) using anexcitation wavelength of 485 nm and emission wavelength, 530 nm. Thepercentage of maximal release is calculated as follows: % maxrelease=(sample/triton treated)*100.

An ADCP assay may be done by labelling target cells with 5 mM CFSE for10 min at room temperature before washing in complete media.CFSE-labeled targets is then opsonized with diluting concentrations ofAb before coculturing at a 1:5 E:T ratio with BMDMs in 96-well platesfor 1 h at 37° C. BMDMs are then labeled with anti-F4/80—allophycocyaninfor 15 min at room temperature and washed with PBS twice. Plates arekept on ice, wells are scraped to collect BMDMs, and phagocytosis isassessed by flow cytometry using a FACSCalibur (BD) to determine thepercentage of F4/80+CFSE+ cells within the F4/80+ cell population.

To decide whether an antibody has immunostimulatory effects, it ispossible to use an in vitro agonism assay. For such an assay thefollowing generic method may be used. Cell culture is in RPMI 1640 media(Gibco™) supplemented with 10% foetal calf serum, glutamine (2 mM),pyruvate (1 mM), penicillin, and streptomycin (100 IU/mL) at 37° C. in5% CO₂. Fresh PBMCs are labelled with 2 mM carboxyfluoresceinsuccinimidyl ester (CFSE). PBMCs are then cultured in a 24-well plate at1×10⁷ cells/mL as described by Römer et al (51) for 48 hours prior tomAb stimulation assays. For PBMC stimulation, round-bottomed 96-wellplates are wet-coated with 0.01 μg/mL of OKT3 antibody (in-house) in PBSfor 4 hours after which excess antibody is discarded and the plates arewashed with PBS. 1×10⁵ PBMCs/well are transferred to the plates andstimulated with 5 μg/mL of test mAb. On day 4 or day 5 post-stimulation,cells are labelled with anti-CD8-APC (BioLegend), and anti-CD4-PE(in-house) and proliferation is assessed by CFSE dilution on aFACSCalibur (BD Biosciences).

To decide whether sequential treatment of a Treg deleting andimmunostimulatory antibody results in improved therapeutic activity, invivo assays with immune competent animals bearing tumours and expressingactivatory and inhibitory Fc gamma receptors can be used. For such anassay, one described in the examples below may be used, for example asillustrated in FIGS. 1 a and 4 c.

As used herein, the term immunostimulatory antibody, orimmunostimulating antibody, refers to an antibody that uponadministration to a subject, such as a human, specifically binds to atarget present on the surface of an effector T cell. The binding of theimmunostimulatory antibody to the target results in stimulation of animmune response, either directly through agonism (e.g. antibodies to TNFsuperfamily agonist receptors such as anti-4-1 BB, OX40 antibodies) orindirectly through blockade of inhibitory signals (e.g. through antibodyblockade of the PD1/PDL1 axis) through stimulation of an effector Tcell. Such an effector T cell can be a CD8+ cell; in such embodiments,the immunostimulatory antibody is a CD8 activating and/or CD8 boostingantibody. Alternatively, or in addition, such an effector T cell can bea CD4⁺ cell; in such embodiments, the immunostimulatory antibody is aCD4 activating and/or CD4 boosting antibody.

We show herein that different antibodies to different targets ofimmunostimulatory or co-inhibitory nature, which act in an Fc:FcγRdependent or independent manner can be used for immune stimulation. Theimmunostimulatory antibody may be an antibody that agonizes an immunestimulatory receptor, such as 4-1 BB, expressed on effector T cells, inan Fc:FcγR dependent manner, or an antibody that antagonises an immunecheckpoint receptor, such as PD-1, expressed on effector T cells, in anFc:FcγR-independent manner.

To decide whether an antibody is an immunostimulatory antibody in themeaning of the present invention, it is possible to use an in vitroassay that demonstrates T cell proliferation in response to mAb. Theassays described above may be used for this purposes.

To decide whether an antibody lacks Treg depleting effects or has a poorTreg depleting effect, it is possible to use in vitro phagocytosisassays or in vivo depletion studies. The assays described in theexamples may be used for this purposes. For example, groups of test micereceive tumour on day 0. When tumours are palpable (or at appropriatestage for tumour model) mice receive the mAb i.v. followed by 3 furtheradministrations i.p. every other day (200 μg final dose, or asestablished for mAb). Mice are then sacrificed 1 or 2 day(s) after thefinal mAb administration and the spleen and tumour are analysed by flowcytometry for TIL content and the frequency of Foxp3+ cells within theCD4+ population in the tumour plotted and spleen (control tissue).

In some embodiments, the Treg depleting antibody is a human antibody.

In some embodiments, the Treg depleting antibody is a humanizedantibody.

In some embodiments, the immunostimulatory antibody is a human antibody.

In some embodiments, the immunostimulatory antibody is a humanizedantibody.

The Treg depleting antibody and the immunostimulatory antibody used incombination in accordance with the present invention may both comprisethe same CDRs since the depleting/immunostimulatory effects may beadjusted by modifications of other parts of the antibody, as alsodiscussed above.

For example, a Treg depleting antibody may be obtained by using anantibody in the form of a human IgG1 antibody; accordingly, in someembodiments, the Treg depleting antibody is a human IgG1 antibody. ATreg depleting antibody may also be obtained by using an antibody in theform of a human IgG1 antibody showing improved binding to one or severalactivatory Fc receptors and/or being engineered for improved binding toone or several activatory Fc receptors; accordingly, in someembodiments, the Treg depleting antibody is an Fc-engineered human IgG1antibody. A Treg depleting antibody may also be obtained by using murineor a humanized murine IgG2a antibody, and accordingly, in someembodiments, the Treg depleting antibody is a humanized murine IgG2aantibody.

Furthermore, an immunostimulatory antibody may be obtained by using anantibody in the form of a human IgG2 antibody, such as a human IgG2bantibody, or in the form of a human IgG4 antibody. Thus, in someembodiments the immunostimulatory antibody is a human IgG2 antibody. Insome embodiments the immunostimulatory antibody is a human IgG2bantibody. In some embodiments the immunostimulatory antibody is a humanIgG4 antibody. An immunostimulatory antibody may also be obtained byusing a murine or a humanized murine IgG1 antibody, and in someembodiments the immunostimulatory antibody is a humanized murine IgG1antibody.

In some embodiments, the immunostimulatory antibody is and antibodyshowing enhanced binding to inhibitory over activatory Fcγ receptors. Insome embodiments, the immunostimulatory antibody is an antibody showingenhanced binding to human FcγRIIB over activatory Fcγ receptors.

In some embodiments, the immunostimulatory antibody is engineered forenhanced binding to inhibitory over activatory Fcγ receptors. In someembodiments, the immunostimulatory antibody is engineered for enhancedbinding to human FcγRIIB over activatory Fcγ receptors.

The target that the Treg depleting antibody of the present invention orthe Treg depleting antibody used in accordance with the presentinvention binds to may be selected from the group consisting of targetsbelonging to the TNFRS. The target belonging to the TNFRS may beselected from the group consisting of 4-1 BB, OX40, and TNFR2.

The target that the Treg depleting antibody of the present invention orthe Treg depleting antibody used in accordance with the presentinvention binds to may alternatively be selected from the groupconsisting of ICOS, GITR, CTLA-4, CD25, and neuroplin-1. In someembodiments, the target is not CD25.

The target that the immunostimulatory antibody of the present inventionor the immunostimulatory used in accordance with the present inventionbinds to may be selected from the group consisting of 4-1 BB and OX40.

The target that the immunostimulatory antibody of the present inventionor the Treg depleting antibody used in accordance with the presentinvention binds to may alternatively be selected from the groupconsisting of ICOS, GITR, CTLA-4, TNFR2, CD25 and PD-1. In someembodiments, the target is not CD25.

In some embodiments of the present invention, at least one target is 4-1BB, which is also denoted CD137 and tumour necrosis factor receptorsuperfamily member 9 (TNFRSF9). 4-1 BB is expressed on Tregs followingactivation of CD4+ and CD8+ T cells and its ligation is required foroptimal protective CD8 T cell responses against viruses and B celllymphoma in mice (11, 12). Anti-4-1 BB specific antibodies enhance theproliferation and survival of antigen-stimulated T cells in vitro and,similar to anti-CD40, anti-4-1 BB mAb promote anti-tumour immunity inpre-clinical cancer models dependent largely on CD8 T cells (12, 13).4-1BB is a downstream target of the Treg lineage-defining transcriptionfactor Foxp3, is expressed on resting Treg cells and is upregulated onTreg activation (14, 15), and it is possible therefore that anti-4-1 BBmay act in part through the depletion of Treg cells. Whether anti-4-1 BBantibody is a depleting or a stimulating antibody is likely to depend onits FcγR usage and in the work leading to the present invention, theinventors carried out in vitro and in vivo experiments to explore theoptimal isotype for a therapeutic anti-4-1 BB mAb in a tumour setting.

We found that although a mIgG1 isotype mAb exerted superior agonisticactivity and direct immune-stimulation of CD8+ T cells compared with amIgG2a version of the same specificity, in established solid tumoursettings the mIgG2a mAb provided optimal therapeutic activity. We foundthat the potency of the mIgG2a mAb is due to intratumoural Tregdepletion. However when depletion was prevented, in mice lackingactivatory FcγR, the therapeutic potential of the mIgG2a was retained.Under these conditions mIgG2a was converted to an agonist by engagingthe inhibitory FcγRIIB. Further to this we established that depletionand agonism are competing mechanisms and that engaging bothsimultaneously led to reduced efficacy. This blunting of activity couldbe overcome through sequential administration of Treg depleting and thenimmunostimulatory isotypes or through Fc engineering to produce adual-activity anti-4-1BB mAb posessing optimal FcγR depleting capacitytogether with FcγR independent agonism. Together, these resultsdemonstrate that immunomodulatory mAb with the same target specificitycan utilise different mechanisms to mediate therapy and that theiroptimal use depends on both isotype, the local FcγR repertoire,abundance and function of immune suppressor and effector cells and theirrelative and absolute expression of target, in the tumormicroenvironment. Importantly, our results further demonstrate thattemporal administration of immunomodulatory mAb, with complementary, butcompeting, mechanisms-of-action may be used to optimize outcome andfurther that it is possible through mAb engineering to generate a singleagent capable of harnessing multiple mechanisms to deliver enhancedtherapeutic efficacy. These results have implications for theadministration of existing and in-development immunomodulatory mAb, andfor the design of next generation immunomodulatory antibodies.

In some embodiments, the Treg depleting antibody molecule is an anti-4-1BB antibody molecule selected from the group presented in Table 1 below.

In some embodiments, the Treg depleting antibody molecule is an anti-4-1BB antibody molecule selected from the group consisting of antibodymolecules comprising 1-6 of the CDRs from each group selected from ofSEQ ID. Nos: 1-6, SEQ ID. Nos: 9-14, SEQ ID. Nos: 17-22, SEQ ID. Nos:25-30, SEQ ID. Nos: 33-38, SEQ ID. Nos: 41-46, SEQ ID. Nos: 49-54, SEQID. Nos: 57-62, SEQ ID. Nos: 65-70, SEQ ID. Nos: 153-158 and SEQ ID.Nos: 163-168.

In some embodiments, the Treg depleting antibody molecule is an anti-4-1BB antibody molecule selected from the group consisting of antibodymolecules comprising the 6 CDRs selected from SEQ ID. Nos: 1-6, SEQ ID.Nos: 9-14, SEQ ID. Nos: 17-22, SEQ ID. Nos: 25-30, SEQ ID. Nos: 33-38,SEQ ID. Nos: 41-46, SEQ ID. Nos: 49-54, SEQ ID. Nos: 57-62, SEQ ID. Nos:65-70, SEQ ID. Nos: 153-158 and SEQ ID. Nos: 163-168.

In some embodiments, the Treg depleting antibody molecule is an anti-4-1BB antibody molecule selected from the group consisting of antibodymolecules comprising a VH selected from the group consisting of SEQ ID.Nos: 7, 15, 23, 31, 39, 47, 55, 63, 71, 159, 161 and 169.

In some embodiments, the Treg depleting antibody molecule is an anti-4-1BB antibody molecule selected from the group consisting of antibodymolecules comprising a VL selected from the group consisting of SEQ ID.Nos: 8, 16, 24, 32, 40, 48, 56, 64, 72, 160, 162 and 170.

In some embodiments, the Treg depleting antibody molecule is an anti-4-1BB antibody molecule selected from the group consisting of antibodymolecules comprising a VH and a VL selected from the group consisting ofSEQ ID. Nos: 7-8, 15-16, 23-24, 31-32, 39-40, 47-48, 55-56, 63-64,71-72, 159-160, 161-162 and 169-170.

In some embodiments, the immunostimulatory antibody molecule is ananti-4-1 BB antibody molecule selected from the group presented in Table1 below.

In some embodiments, the immunostimulatory antibody molecule is ananti-4-1 BB antibody molecule selected from the group consisting ofantibody molecules comprising 1-6 of the CDRs from each group SEQ ID.Nos: 1-6, SEQ ID. Nos: 9-14, SEQ ID. Nos: 17-22, SEQ ID. Nos: 25-30, SEQID. Nos: 33-38, SEQ ID. Nos: 41-46, SEQ ID. Nos: 49-54, SEQ ID. Nos:57-62, SEQ ID. Nos: 65-70, SEQ ID. Nos: 153-158 and SEQ ID. Nos:163-168.

In some embodiments, the immunostimulatory antibody molecule is ananti-4-1 BB antibody molecule selected from the group consisting ofantibody molecules comprising the 6 CDRs selected from SEQ ID. Nos: 1-6,SEQ ID. Nos: 9-14, SEQ ID. Nos: 17-22, SEQ ID. Nos: 25-30, SEQ ID. Nos:33-38, SEQ ID. Nos: 41-46, SEQ ID. Nos: 49-54, SEQ ID. Nos: 57-62, SEQID. Nos: 65-70, 153-158 and SEQ ID. Nos: 163-168.

In some embodiments, the immunostimulatory antibody molecule is ananti-4-1 BB antibody molecule selected from the group consisting ofantibody molecules comprising a VH selected from the group consisting ofSEQ ID. Nos: 7, 15, 23, 31, 39, 47, 55, 63, 71, 159, 161 and 169.

In some embodiments, the immunostimulatory antibody molecule is ananti-4-1 BB antibody molecule selected from the group consisting ofantibody molecules comprising a VL selected from the group consisting ofSEQ ID. Nos: 8, 16, 24, 32, 40, 48, 56, 64, 72, 160, 162 and 170.

In some embodiments, the immunostimulatory antibody molecule is ananti-4-1 BB antibody selected from the group consisting of antibodymolecules comprising a VH and VL selected from the group consisting ofSEQ ID. Nos: 7-8, 15-16, 23-24, 31-32, 39-40, 47-48, 55-56, 63-64,71-72, 159-160, 161-162 and 169-170.

TABLE 1 4-1BB antibodies SEQ. Antibody Sequence ID. NO: 2-A11 VH-CDR1FSSNEMSWVRQAPG 1 VH-CDR2 SGSIGYADSVKGR 2 VH-CDR3 ARDRMVRGVSNWFDP 3VL-CDR1 CTGSSSNIGAGYDVN 4 VL-CDR2 GNFNRPS 5 VL-CDR3 CQSYDSRLSGSV 6 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSSNEMSWVR- 7QAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAVYYCARDRMVRGVSNWFDP WGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCTGSSSNI- 8 GAGYDVNWYQQLPGTAPKLLIYGNFNRPSGVPDRFSG-SKSGTSASLAISGLR- SEDEADYYCQSYDSRLSGSVFGGGTKLTVLG 2-D01 VH-CDR1FTFGDYAVAWFRQAPG 9 VH-CDR2 ITDYADPVKGR 10 VH-CDR3 ARNYGGYYYYGMDV 11VL-CDR1 CTGSSSNIGAGYDVH 12 VL-CDR2 GTAPKLLIYGTNNRPS 13 VL-CDR3CAAWDGSLSGRV 14 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFGDYAVAWFR- 15QAPGKGLEWVSIVSGSGTITDYADPVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYYCARNYGGYYYYG-MDVWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCTGSSSNI- 16GAGYDVHWYQQLPGTAPKLLIYGTNNRPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCAAWDGSLSGRVFGGGTKLTVLG 5-A09 VH-CDR1 FSSNYMSWVRQAPG 17 VH-CDR2SSISSGSSYIYYADSVKGR 18 VH-CDR3 AKEPPAYREGIDY 19 VL-CDR1 CSGSSSNIANNYVS20 VL-CDR2 DNTNRPS 21 VL-CDR3 CASWDDSLSGPV 22 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSSNYMSWVR- 23QAPGKGLEWVSSISSGSSYIYYADSVKGRFTISID- NSKNTLYLQMNSLRAEDTAVYYCAKEP-PAYREGIDYWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCSGSSSNI- 24ANNYVSWYQQLPGTAPKLLIYDNTNRPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCASWDDSLSGPVFGGGTKLTVLG 6-A01 VH-CDR1 FSSYSMNWVRQAPG 25 VH-CDR2AVISYDGSNKYYADSMKGR 26 VH-CDR3 ARDSYLGWCPAGSCTGIDY 27 VL-CDR1CSGSSSNIGNNAVN 28 VL-CDR2 YDDLLPS 29 VL-CDR3 CAAWDDSLSGWV 30 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVR- 31QAPGKGLEWVAVISYDGSNKYYADSMKGRFTISRD-NSKNTLYLQMNSLRAEDTAVYYCARDSYLGWCPAGSCT- GIDYWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCSGSSS- 32 NIGNNAVNWYQQLPGTAPKLLIYYDDLLPSGVPDRFSG-SKSGTSASLAISGLR- SEDEADYYCAAWDDSLSGWVFGGGTKLTVLG 6-A11 VH-CDR1FSNYVLTWVRQSPG 33 VH-CDR2 SGSGYNTYHADSVKGR 34 VH-CDR3 ARAAYDSSGYADAFDI35 VL-CDR1 CSGSSSNIGSNYVY 36 VL-CDR2 GDNRRPS 37 VL-CDR3 CAAWDDSLNGWV 38VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYVLT- 39WVRQSPGKGLEWVSGISGSGYNTYHADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAVYYCARAAYDSSGYADAFD- IWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVY- 40 WYQQLPGTAPKLLIYGDNRRPSGVPDRFSG-SKSGTSASLAISGLR- SEDEADYYCAAWDDSLNGWVFGGGTKLTVLG 6-F05 VH-CDR1RLSCAASGFTFSDYYMSWVRQAPG 41 VH-CDR2 ANIKQDGSEKYYGDSATGR 42 VH-CDR3AKEERIGTYYY 43 VL-CDR1 CSGSSFNIGSNYVY 44 VL-CDR2 KNNQRPS 45 VL-CDR3CAAWDDSLNGQV 46 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYYMSWVR- 47QAPGKGLEWVANIKQDGSEKYYGDSATGRFTISRD-NSKNTLYLQMNSLRAEDTAVYYCAKEERIGTYYYWGQGTL VTVSS VLQSVLTQPPSASGTPGQRVTISCSGSSFNIGSNYVY- 48 WYQQLPGTAPKLLIYKNNQRPSGVPDRFSG-SKSGTSASLAISGLR- SEDEADYYCAAWDDSLNGQVFGGGTKLTVLG 6-H05 VH-CDR1FSDYYMTWIRQAPG 49 VH-CDR2 SSISSSSSYIYYADSVKGR 50 VH-CDR3ASTQTPYGSGNYPIYYYYGMDV 51 VL-CDR1 CSGSRSNIRSNSVS 52 VL-CDR2 GNSNRPS 53VL-CDR3 CGTWDDRLNRPV 54 VH EVQLLESGGGLVQPGGSLRLS- 55CAASGFTFSDYYMTWIRQAPGKGLEWVSSISSSSSYIY- YADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAVYYCASTQTPYGSGNYPIY- YYYGMDVWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCSGSRSNIRSNSVSWYQQL 56PGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLR-SEDEADYYCGTWDDRLNRPVFGGGTKLTVLG 7-B08 VH-CDR1 FSSYWMSWVRQTPG 57 VH-CDR2SAINAAGDFQSYADSVRGR 58 VH-CDR3 ARGDGYNYFDI 59 VL-CDR1 CSGSSSNIGSNYVY 60VL-CDR2 GNSNRPS 61 VL-CDR3 CQSYDSSLSGLV 62 VH EVQLLESGGGLVQPGGSLRLS- 63CAASGFTFSSYWMSWVRQTPGKGLEWVSAINAAGDFQSYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAMYYCAR- GDGYNYFDIWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVY- 64 WYQQLPGTAPKLLIYGNSNRPSGVPDRFSG-SKSGTSASLAISGLR- SEDEADYYCQSYDSSLSGLVFGGGTKLTVLG 6-A06 VH-CDR1FSRYEMNWVRQAPG 65 VH-CDR2 SGINWNGGSTGYADSVKGR 66 VH-CDR3 ARHRNPDPLDAFDI67 VL-CDR1 CTGSSSNIGAGYDVH 68 VL-CDR2 SNNQRPS 69 VL-CDR3 CASYTSISTVL 70VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYEMNWVR- 71QAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAMYYCARHRNPDPLDAFD- IWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCTGSSSNI- 72 GAGYDVHWYQQLPGTAPKLLIYSNNQRPSGVPDRFSG-SKSGTSASLAISGLR- SEDEADYYCASYTSISTVLFGGGTKLTVLG 5-B02 VH-CDR1FSSYAMHWVRQAPG 153 VH-CDR2 AVISYDGSNKYYADSVKGR 154 VH-CDR3 TRPLKDDPDAFDI155 VL-CDR1 CSGSSSNIGSYAVN 156 VL-CDR2 RNNQRPS 157 VL-CDR3 CFSYAGGNTWV158 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVR- 159QAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAVYYCTRPLKDDPDAFD- IWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCSGSSSNIGSYAVNWYQQLPGTAP- 160KLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLR- SEDEADYYCFSYAGGNTWVFGGGTKLTVLG2-C08 VH-CDR1 FSSYEMNWVRQAPG 163 VH-CDR2 SAISGSAGSTYYADSVKGR 164 VH-CDR3ATYPKEKTLHGGRYPYYGLDL 165 VL-CDR1 CSGSSSNIGSNTVN 166 VL-CDR2 DNNKRPL 167VL-CDR3 CATWDDSLSGPV 168 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYEMNWVR- 169QAPGKGLEWVSGINWNGGSTGYADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAMYYCARHRNPDPLDAFD- IWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCTGSSSNI- 170GAGYDVHWYQQLPGTAPKLLIYSNNQRPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCASYTSISTVLFGGGTKLTVLG SAP3-6 VHMKCSWVMFFLMAVVTGVNSEVQLQQSGAELVKP- 161GASVKLSCTASGFNIKDSYMYWVKQRPEQGLEWIGRI- YPANGDTKYDPKFQGKATITADTSS-NTAYLQLSSLASEDTAVYYCTRGYG- SNFFDYWGQGTTLTVSS VLMETDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRT- 162TISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYRASN- LESGIPARFSGSGSRTDFTLTINPVE-ADDVATYYCQQSNEDPFTFGGGTKLEIK

In some embodiments, the Treg depleting antibody molecule is ananti-OX40 antibody molecule selected from the group presented in Table 2below.

In some embodiments, the Treg depleting antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising 1-6 of the CDRs from each group selectedfrom SEQ ID. Nos: 73-78, SEQ ID. Nos:81-86, SEQ ID. Nos:89-94, SEQ ID.Nos:97-102, SEQ ID. Nos:105-110, SEQ ID. Nos:113-118, SEQ ID.Nos:121-126, SEQ ID. Nos:129-134, SEQ ID. Nos:137-142, SEQ ID.Nos:145-150 and SEQ ID. Nos:171-176.

In some embodiments, the Treg depleting antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising the 6 CDRs from each group selected fromSEQ ID. Nos: 73-78, SEQ ID. Nos:81-86, SEQ ID. Nos:89-94, SEQ ID.Nos:97-102, SEQ ID. Nos:105-110, SEQ ID. Nos:113-118, SEQ ID.Nos:121-126, SEQ ID. Nos:129-134, SEQ ID. Nos: 137-142, SEQ ID.Nos:145-150 and SEQ ID. Nos:171-176.

In some embodiments, the Treg depleting antibody molecule is ananti-OX40 antibody molecule selected from the group comprising a VHselected from the group consisting of SEQ ID. Nos: 79, 87, 95, 103, 111,119, 127, 135, 143, 151 and 177.

In some embodiments, the Treg depleting antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising a VL selected from the group consisting ofSEQ ID. Nos: 80, 88, 96, 104, 112, 120, 128, 136, 144, 152 and 178.

In some embodiments, the Treg depleting antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising a VH and a VL selected from the groupconsisting of SEQ ID. Nos: 79-80, 87-88, 95-96, 103-104, 111-112,119-120, 127-128, 135-136, 143-144, 151-152 and 177-178.

In some embodiments, the immunostimulatory antibody molecule is ananti-OX40 antibody molecule selected from the group presented in Table 2below.

In some embodiments, the immunostimulatory antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising 1-6 of the CDRs from each group selectedfrom SEQ ID. Nos: 73-78, SEQ ID. Nos: 81-86, SEQ ID. Nos: 89-94, SEQ ID.Nos: 97-102, SEQ ID. Nos: 105-110, SEQ ID. Nos: 113-118, SEQ ID. Nos:121-126, SEQ ID. Nos: 129-134, SEQ ID. Nos: 137-142, SEQ ID. Nos:145-150 and SEQ ID. Nos: 171-176.

In some embodiments, the immunostimulatory antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising the 6 CDRs selected from SEQ ID. Nos:73-78, SEQ ID. Nos: 81-86, SEQ ID. Nos: 89-94, SEQ ID. Nos: 97-102, SEQID. Nos: 105-110, SEQ ID. Nos: 113-118, SEQ ID. Nos: 121-126, SEQ ID.Nos: 129-134, SEQ ID. Nos: 137-142, 145-150 and SEQ ID. Nos: 171-176.

In some embodiments, the immunostimulatory antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising a VH selected from the group consisting ofSEQ ID. Nos: 79, 87, 95, 103, 111, 119, 127, 135, 143, 151 and 177.

In some embodiments, the immunostimulatory antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising a VL selected from the group consisting ofSEQ ID. Nos: 80, 88, 96, 104, 112, 120, 128, 136, 144, 152 and 178.

In some embodiments, the immunostimulatory antibody molecule is ananti-OX40 antibody molecule selected from the group consisting ofantibody molecules comprising a VH and a VL selected from the groupconsisting of SEQ ID. Nos: 79-80, 87-88, 95-96, 103-104, 111-112,119-120, 127-128, 135-136, 143-144, 151-152 and 177-178.

TABLE 2 OX40 antibodies SEQ. Antibody ID. NO: 1-D08 VH-CDR1FSSYAMSWVRQAPG  73 VH-CDR2 SGINGYGDTPKDADSVKGR  74 VH-CDR3ATLYCGGGGCYPDS  75 VL-CDR1 CTGSRSNIGAGYDVH  76 VL-CDR2 DYDEQPS  77VL-CDR3 CAAWDDSLNGVV  78 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR-  79QAPGKGLEWVSGINGYGDTPKDADSVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYY-CATLYCGGGGCYPDSWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCTGSRSNI-  80GAGYDVHWYQQLPGTAPKLLIYDYDEQPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCAAWDDSLNGVVFGGGTKLTVLG 2-A02 VH-CDR1 FSGYWMTWVRQAPG  81 VH-CDR2SSISSSSSYIYYADSVKGR  82 VH-CDR3 TSSNPFYGMDV  83 VL-CDR1 CSGSSSNIGNNYVS 84 VL-CDR2 YDDLLPS  85 VL-CDR3 CAAWDDSLNGGV  86 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSGYWMTWVR-  87QAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYYCTSSNPFYG-MDVWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCSGSSS-  88NIGNNYVSWYQQLPGTAPKLLIYYDDLLPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCAAWDDSLNGGVFGGGTKLTVLG 2-D07 VH-CDR1 FSDYYMSWVRQAPG  89 VH-CDR2SSITGTAGLTYNADSVKGR  90 VH-CDR3 ARMDWGYGNFDY  91 VL-CDR1 CSGSSSNIGSYTVN 92 VL-CDR2 GNNNRPS  93 VL-CDR3 CATWDDSLSGPV  94 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYYMSWVR-  95QAPGKGLEWVSSITGTAGLTYNADSVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYYCARMDWGYG-NFDYWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCSGSSS-  96NIGSYTVNWYQQLPGTAPKLLIYGNNNRPSGVPDRFSG- SKSGTSASLAISGLRSEDEADYY-CATWDDSLSGPVFGGGTKLTVLG 2-F02 VH-CDR1 FSDYEMNWVRQAPG  97 VH-CDR2AVISYDGSNKYYADSVKGR  98 VH-CDR3 AANSPFDP  99 VL-CDR1 CTGSSSNIGAGYDVH 100VL-CDR2 NDNVRPS 101 VL-CDR3 CAAWDANLSGWV 102 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMNWVR- 103QAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAVYYCAANSPFDPWGQGTLVT VSS VLQSVLTQPPSASGTPGQRVTISCTGSSSNI- 104GAGYDVHWYQQLPGTAPKLLIYNDNVRPSGVPDRFSG- SKSGTSASLAISGLRSEDEADYYCAAW-DANLSGWVFGGGTKLTVLG 2-F10 VH-CDR1 FSSYEMNWVRQAPG 105 VH-CDR2AVISYDGSNKYYADSVKGR 106 VH-CDR3 AANSPFDP 107 VL-CDR1 CTGSSSNIGAGYDVH 108VL-CDR2 SNNQRPS 109 VL-CDR3 CAAWDDSLSGWV 110 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVR- 111QAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD-NSKNTLYLQMNSLRAEDTAMYYCAANSPFDPWGQGTLVT VSS VLQSVLTQPPSASGTPGQRVTISCTGSSSNI- 112GAGYDVHWYQQLPGTAPKLFIYSNNQRPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCAAWDDSLSGWVFGGGTKLTVLG 5-D11 VH-CDR1 FDNHWMSWVRQAPG 113 VH-CDR2SSISSSSSYIYYADSVKGR 114 VH-CDR3 AREDWSFDL 115 VL-CDR1 CSGSSSNIGNNAVN 116VL-CDR2 GNSNRPS 117 VL-CDR3 CQTFDVSQNAWV 118 VH EVQLLESGGGLVQPGGSLRLS-119 CAASGFTFDNHWMSWVRQAPGKGLEWVSSISSSSSYIY- YADSVKGRSTISRD-NSKNTLYLQMNSLRAEDTAMYYCAREDWS- FDLWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCSGSSS- 120 NIGNNAVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSG-SKSGTSASLAISGLR- SEDEADYYCQTFDVSQNAWVFGGGTKLTVLG 6-D12 VH-CDR1FSNSDMNWVRQAPG 121 VH-CDR2 SAISNSGDGTYYADSVKGR 122 VH-CDR3 REKTWGAAFDI123 VL-CDR1 CTGSSSNIGAGYDVH 124 VL-CDR2 SQNLRPS 125 VL-CDR3 CQSYDSSLSGSV126 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSNSDMNWVR- 127QAPGKGLEWVSAISNSGDGTYYADSVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYYCAREKTWGAAFD-IWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCTGSSSNI- 128GAGYDVHWYQQLPGTAPKLLIYSQNLRPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCQSYDSSLSGSVFGGGTKLTVLG 6-F03 VH-CDR1 FSDYTMNWVRQAPG 129 VH-CDR2SAISGSGGSTYYPDSVKGR 130 VH-CDR3 ARGGGYWPFDP 131 VL-CDR1 CSGSSSTIGNNAIN132 VL-CDR2 RDNQRPS 133 VL-CDR3 CQSYDSSLRVVV 134 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYTMNWVR- 135QAPGKGLEWVSAISGSGGSTYYPDSVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYYCARGG-GYWPFDPWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCSGSSSTIGNNAIN- 136WYQQLPGTAPKLLIYRDNQRPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCQSYDSSLRVVVFGGGTKLTVLG 6-F04 VH-CDR1 FSSYAMSWVRQAPG 137 VH-CDR2SSISSSSSYIYYADSVKGR 138 VH-CDR3 VRGTSLDAFDI 139 VL-CDR1 CSGSSSNIGNTYVS140 VL-CDR2 YDDLLPS 141 VL-CDR3 CAAWDDSLSGVV 142 VHEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR- 143QAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYYCVRGTSLDAFD-IWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCSGSSSNIGN- 144TYVSWYQQLPGTAPKLLIYYDDLLPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCAAWDDSLSGVVFGGGTKLTVLG 7-A07 VH-CDR1 FSDYYMSWIRQAPG 145 VH-CDR2SSISSSSSYISYADSMKGR 146 VH-CDR3 ATSEAAAADYFDY 147 VL-CDR1CTGSSSNIGAGYDVH 148 VL-CDR2 DNNKRPS 149 VL-CDR3 CAAWDDSLNGPV 150 VHEVQLLESGGGLVQPGGSLRLS- 151 CAASGFTFSDYYMSWIRQAPGKGLEWVSSISSSSSYIS-YADSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY- CATSEAAAADYFDYWGQGTLVTVSS VLQSVLTQPPSASGTPGQRVTISCTGSSSNI- 152GAGYDVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSG- SKSGTSASLAISGLR-SEDEADYYCAAWDDSLNGPVFGGGTKLTVLG 1-G06 VH-CDR1 SSYAMSWVRQAPG 171 VH-CDR2AHTNEDGSDKKYVDSVKGR 172 VH-CDR3 ARDGSGYSSGWYFDY 173 VL-CDR1CTGTTSNLGAGYDVH 174 VL-CDR2 SNNQRPSGVPDRFS 175 VL-CDR3 CQSYDSSLSALV 176VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR- 177QAPGKGLEWVAHTNEDGSDKKYVDSVKGRFTISRD- NSKNTLYLQMNSLRAEDTAVYYCARDGSGY-SSGWYFDYWGQGTLVTVSS VL QSVLTQPPSASGTPGQRVTISCTGTTSNL- 178GAGYDVHWYQQLPGTAPKLLIYSNNQRPSGVPDRFSG-SKSGTSASLAISGLRSEDEADYYCQSYDSSLSAL- VFGGGTKLTVLG

In some embodiments, the immunostimulatory antibody is an anti-PD1antibody, preferably a human anti-PD1 antibody. The anti-PD1 antibodymay be selected from the group consisting of nivolumab andpembrolizumab.

In some embodiments, the immunostimulatory antibody is an anti-PD1antibody, preferably a human anti-PD1 antibody. The anti-PD1 antibodymay be selected from the group consisting of nivolumab andpembrolizumab.

In some embodiments, the immunostimulatory antibody is an anti-PDL1antibody, preferably a human anti-PDL1 antibody. The anti-PDL1 antibodymay be atezolizumab.

In some embodiments, the immunostimulatory antibody is an anti-CTLA-4antibody, preferably a human anti-CTLA-4 antibody. The anti-CTLA-4antibody may be selected from the group consisting of ipilimumab andtremilimumab.

The Treg depleting antibody is administered to the subject, such as ahuman, prior to administration of the immunostimulatory antibody. Thismeans that the Treg depleting antibody is administered to the tumourfirst in order to achieve the Treg depleting effect. Once the Tregdepleting effect is manifested, the immunostimulatory antibody isadministered. This sequential administration may be achieved by temporalseparation of the two antibodies. Alternatively, or in combination withthe first option, the sequential administration may also be achieved byspatial separation of the two antibodies, by administration of the Tregdepleting antibody in a way, such as intratumoural, so that it reachesthe tumour prior to the immunostimulatory antibody, which is thenadministered in a way, such as systemically, so that it reaches thetumour after the Treg depleting antibody.

It would be known to the person skilled in medicine, that medicines canbe modified with different additives, for example to change the rate inwhich the medicine is absorbed by the body; and can be modified indifferent forms, for example to allow for a particular administrationroute to the body.

Accordingly, we include that the composition, and/or antibody, and/oragent, and/or medicament of the invention may be combined with anexcipient and/or a pharmaceutically acceptable carrier and/or apharmaceutically acceptable diluent and/or an adjuvant.

We also include that the composition, and/or antibody, and/or agent,and/or medicament of the invention may be suitable for parenteraladministration including aqueous and/or non-aqueous sterile injectionsolutions which may contain anti-oxidants, and/or buffers, and/orbacteriostats, and/or solutes which render the formulation isotonic withthe blood of the intended recipient; and/or aqueous and/or non-aqueoussterile suspensions which may include suspending agents and/orthickening agents. The composition, and/or antibody, and/or agent,and/or medicament of the invention may be presented in unit-dose ormultidose containers, for example sealed ampoules and vials, and may bestored in a freeze-dried (i.e. lyophilised) condition requiring only theaddition of the sterile liquid carrier, for example water forinjections, immediately prior to use.

Extemporaneous injection solutions and suspensions may be prepared fromsterile powders, and/or granules, and/or tablets of the kind previouslydescribed.

For parenteral administration to human patients, the daily dosage levelof the Treg depleting antibody and/or the immunostimulatory antibodywill usually be from 1 mg/kg bodyweight of the patient to 20 mg/kg, orin some cases even up to 100 mg/kg administered in single or divideddoses. Lower doses may be used in special circumstances, for example incombination with prolonged administration. The physician in any eventwill determine the actual dosage which will be most suitable for anyindividual patient and it will vary with the age, weight and response ofthe particular patient. The above dosages are exemplary of the averagecase. There can, of course, be individual instances where higher orlower dosage ranges are merited and such are within the scope of thisinvention.

Typically, the composition and/or medicament of the invention willcontain the Treg depleting antibody and/or the immunostimulatoryantibody at a concentration of between approximately 2 mg/ml and 150mg/ml or between approximately 2 mg/ml and 200 mg/ml. In a preferredembodiment, the medicaments and/or compositions of the invention willcontain the Treg depleting antibody and/or the immunostimulatoryantibody at a concentration of 10 mg/ml.

Generally, in humans, oral or parenteral administration of thecomposition, and/or antibody, and/or agent, and/or medicament of theinvention is the preferred route, being the most convenient. Forveterinary use, the composition, and/or antibody, and/or agent and/ormedicament of the invention are administered as a suitably acceptableformulation in accordance with normal veterinary practice and theveterinary surgeon will determine the dosing regimen and route ofadministration which will be most appropriate for a particular animal.Thus, the present invention provides a pharmaceutical formulationcomprising an amount of an antibody and/or agent of the inventioneffective to treat various conditions (as described above and furtherbelow). Preferably, the composition, and/or antibody, and/or agent,and/or medicament is adapted for delivery by a route selected from thegroup comprising: intravenous; intramuscular; subcutaneous.

The present invention also includes composition, and/or antibody, and/oragent, and/or medicament comprising pharmaceutically acceptable acid orbase addition salts of the polypeptide binding moieties of the presentinvention. The acids which are used to prepare the pharmaceuticallyacceptable acid addition salts of the aforementioned base compoundsuseful in this invention are those which form non-toxic acid additionsalts, i.e. salts containing pharmacologically acceptable anions, suchas the hydrochloride, hydrobromide, hydroiodide, nitrate, sulphate,bisulphate, phosphate, acid phosphate, acetate, lactate, citrate, acidcitrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate,saccharate, benzoate, methanesulphonate, ethanesulphonate,benzenesulphonate, p-toluenesulphonate and pamoate [i.e.1,1′-methylene-bis-(2-hydroxy-3 naphthoate)] salts, among others.Pharmaceutically acceptable base addition salts may also be used toproduce pharmaceutically acceptable salt forms of the agents accordingto the present invention. The chemical bases that may be used asreagents to prepare pharmaceutically acceptable base salts of thepresent agents that are acidic in nature are those that form non-toxicbase salts with such compounds. Such non-toxic base salts include, butare not limited to those derived from such pharmacologically acceptablecations such as alkali metal cations (e.g. potassium and sodium) andalkaline earth metal cations (e.g. calcium and magnesium), ammonium orwater-soluble amine addition salts such asN-methylglucamine-(meglumine), and the lower alkanolammonium and otherbase salts of pharmaceutically acceptable organic amines, among others.The agents and/or polypeptide binding moieties of the invention may belyophilised for storage and reconstituted in a suitable carrier prior touse. Any suitable lyophilisation method (e.g. spray drying, cake drying)and/or reconstitution techniques can be employed. It will be appreciatedby those skilled in the art that lyophilisation and reconstitution canlead to varying degrees of antibody activity loss (e.g. withconventional immunoglobulins, IgM antibodies tend to have greateractivity loss than IgG antibodies) and that use levels may have to beadjusted upward to compensate. In one embodiment, the lyophilised(freeze dried) polypeptide binding moiety loses no more than about 20%,or no more than about 25%, or no more than about 30%, or no more thanabout 35%, or no more than about 40%, or no more than about 45%, or nomore than about 50% of its activity (prior to lyophilisation) whenre-hydrated.

The combination of a Treg depleting antibody molecule andimmunostimulatory antibody molecule, wherein the Treg depleting antibodymolecule is administered to a subject prior to administration of theimmunostimulatory antibody molecule to the subject can be used use inthe treatment of cancer.

We include that the subject could be mammalian or non-mammalian.Preferably, the mammalian subject is a human or is a non-mammalian, suchas a horse, or a cow, or a sheep, or a pig, or a camel, or a dog, or acat. Most preferably, the mammalian subject is a human.

By “exhibit”, we include that the subject displays a cancer symptomand/or a cancer diagnostic marker, and/or the cancer symptom and/or acancer diagnostic marker can be measured, and/or assessed, and/orquantified.

It would be readily apparent to the person skilled in medicine what thecancer symptoms and cancer diagnostic markers would be and how tomeasure and/or assess and/or quantify whether there is a reduction orincrease in the severity of the cancer symptoms, or a reduction orincrease in the cancer diagnostic markers; as well as how those cancersymptoms and/or cancer diagnostic markers could be used to form aprognosis for the cancer.

Cancer treatments are often administered as a course of treatment, whichis to say that the therapeutic agent is administered over a period oftime. The length of time of the course of treatment will depend on anumber of factors, which could include the type of therapeutic agentbeing administered, the type of cancer being treated, the severity ofthe cancer being treated, and the age and health of the subject, amongstothers reasons.

By “during the treatment”, we include that the subject is currentlyreceiving a course of treatment, and/or receiving a therapeutic agent,and/or receiving a course of a therapeutic agent.

In some embodiments the cancer to be treated in accordance with thepresent invention is a solid tumour.

In some embodiments, the cancer is selected from the group consisting ofsarcomas, carcinomas and lymphomas.

In some embodiments, the cancer is selected from the group consisting ofsquamous cell carcinoma (SCC), thymoma, neuroblastoma or ovarian cancer.

Each one of the above described cancers is well-known, and the symptomsand cancer diagnostic markers are well described, as are the therapeuticagents used to treat those cancers. Accordingly, the symptoms, cancerdiagnostic markers, and therapeutic agents used to treat the abovementioned cancer types would be known to those skilled in medicine.

Clinical definitions of the diagnosis, prognosis and progression of alarge number of cancers rely on certain classifications known asstaging. Those staging systems act to collate a number of differentcancer diagnostic markers and cancer symptoms to provide a summary ofthe diagnosis, and/or prognosis, and/or progression of the cancer. Itwould be known to the person skilled in oncology how to assess thediagnosis, and/or prognosis, and/or progression of the cancer using astaging system, and which cancer diagnostic markers and cancer symptomsshould be used to do so.

By “cancer staging”, we include the Rai staging, which includes stage 0,stage I, stage II, stage III and stage IV, and/or the Binet staging,which includes stage A, stage B and stage C, and/or the Ann Arbourstaging, which includes stage I, stage II, stage III and stage IV.

It is known that cancer can cause abnormalities in the morphology ofcells. These abnormalities often reproducibly occur in certain cancers,which means that examining these changes in morphology (otherwise knownas histological examination) can be used in the diagnosis or prognosisof cancer. Techniques for visualizing samples to examine the morphologyof cells, and preparing samples for visualization, are well known in theart; for example, light microscopy or confocal microscopy.

By “histological examination”, we include the presence of small, maturelymphocyte, and/or the presence of small, mature lymphocytes with anarrow border of cytoplasm, the presence of small, mature lymphocyteswith a dense nucleus lacking discernible nucleoli, and/or the presenceof small, mature lymphocytes with a narrow border of cytoplasm, and witha dense nucleus lacking discernible nucleoli, and/or the presence ofatypical cells, and/or cleaved cells, and/or prolymphocytes.

It is well known that cancer is a result of mutations in the DNA of thecell, which can lead to the cell avoiding cell death or uncontrollablyproliferating. Therefore, examining these mutations (also known ascytogenetic examination) can be a useful tool for assessing thediagnosis and/or prognosis of a cancer. An example of this is thedeletion of the chromosomal location 13q14.1 which is characteristic ofchronic lymphocytic leukaemia. Techniques for examining mutations incells are well known in the art; for example, fluorescence in situhybridization (FISH).

By “cytogenetic examination”, we include the examination of the DNA in acell, and, in particular the chromosomes. Cytogenetic examination can beused to identify changes in DNA which may be associated with thepresence of a refractory cancer and/or relapsed cancer. Such mayinclude: deletions in the long arm of chromosome 13, and/or the deletionof chromosomal location 13q14.1, and/or trisomy of chromosome 12, and/ordeletions in the long arm of chromosome 12, and/or deletions in the longarm of chromosome 11, and/or the deletion of 11q, and/or deletions inthe long arm of chromosome 6, and/or the deletion of 6q, and/ordeletions in the short arm of chromosome 17, and/or the deletion of 17p,and/or the t(11:14) translocation, and/or the (q13:q32) translocation,and/or antigen gene receptor rearrangements, and/or BCL2 rearrangements,and/or BCL6 rearrangements, and/or t(14:18) translocations, and/ort(11:14) translocations, and/or (q13:q32) translocations, and/or (3:v)translocations, and/or (8:14) translocations, and/or (8:v)translocations, and/or t(11:14) and (q13:q32) translocations.

It is known that subjects with cancer exhibit certain physical symptoms,which are often as a result of the burden of the cancer on the body.Those symptoms often reoccur in the same cancer, and so can becharacteristic of the diagnosis, and/or prognosis, and/or progression ofthe disease. A person skilled in medicine would understand whichphysical symptoms are associated with which cancers, and how assessingthose physical systems can correlate to the diagnosis, and/or prognosis,and/or progression of the disease. By “physical symptoms”, we includehepatomegaly, and/or splenomegaly.

BRIEF DESCRIPTION OF THE DRAWINGS

In the examples below, reference is made to the following figures:

FIG. 1 . Anti-4-1BB mIgG2a mAb, but not mIgG1, confer survival benefitin multiple cancer models. FIG. 1A: Groups of BALB/c mice werechallenged with 5×10⁵ CT26 s.c. on day 0. When tumours were palpablemice received anti-4-1BB (LOB12.0) mIgG1, mIgG2a or PBS control i.v.followed by 3 further administrations i.p. every other day (200 μg finaldose). FIG. 1B: Groups of A/J mice were challenged with 2×10⁶ NXS2 cellss.c. and received 200 μg anti-4-1 BB mAb or isotype control mAb i.p.when tumour was palpable. A second dose of 200 μg was given 3 dayslater. In both experimental models tumour growth was monitored and miceculled when mean tumour area exceeded 225 mm². Data are expressed astumour area (mm²) on the days after tumour challenge as indicated; eachline represents an individual mouse. Panels on the right show percentagesurvival to the humane end-point. Data represent examples of at least 2independent experiments where n=5 mice per group.

FIG. 2 . Anti-4-1 BB mIgG1 exerts agonist activity in vitro and in vivo.FIG. 2A: Splenocytes from Foxp3-GFP mice either sorted to remove GFP+cells (−T_(reg)) or not (+T_(reg)) were incubated with 0.1 μg/mlanti-CD3 and the indicated concentrations of either anti-4-1 BB(LOB12.0) mIgG1 or mIgG2a as indicated. Incorporation of [³H]-thymidinewas measured during the last 16 hours of a 72 hour culture. FIG. 2BSplenocytes from C57BL/6 mice were similarly incubated with 0.1 μg/mlanti-CD3 and the indicated concentrations of anti-4-1 BB mIgG1, mIgG2aor a 1:1 mix of the two prior to assessment of [³H]-thymidineincorporation. Data in FIG. 2A and FIG. 2B show mean (+/−SEM) counts perminute of triplicate wells. FIG. 2C: Groups of mice received 5 mg OVAand 200 μg anti-4-1 BB mIgG1 or mIgG2a i.p. on day 0. SIINFEKL-specificT-cell responses in peripheral blood were quantified by flow cytometryand expressed as a % of total CD8+ cells. Data are from three separateexperiments, and show time course of response (mean±SEM, 6 mice pergroup) and peak of response (mean and individual responses, 9 mice pergroup, *p=0.023). FIG. 2D: Groups of A/J mice were challenged with 2×10⁶NXS2 cells s.c. on day 0 and received 200 μg anti-4-1BB mAb or isotypecontrol mAb i.p. and control (SI INFEKL; left panel) or TH (FETFEAKI;right panel) peptide on day 3. A second dose of mAb (200 μg) was givenon day 6. Data in FIG. 2B and FIG. 2C represent examples of at least 2experiments where n=5 mice per group.

FIG. 3 . Mouse and human tumour resident Treg cells preferentiallyexpress 4-1 BB. FIG. 3A:Immunofluorescence microscopy image showing 4-1BB expressing intratumoural Foxp3+Treg in CT26 tumour (left panel).Scale bar=50 μM. Flow cytometry histograms demonstrating 4-1 BBexpression on T cell subsets from TILs and splenocytes (right panels).4-1BB expression (black line) on CD4+Foxp3+(inset top panels),CD4+Foxp3− (inset middle panels) and CD8+ T cells (inset bottom panels),against isotype control (grey line). Cells were isolated from micebearing CT26 tumour. FIG. 3B: Samples of freshly excised ovariantumours, ascites and blood were obtained from patients at surgery andcompared to healthy PBMC. Tumour samples were minced and digested beforeseparation with a density gradient. Matched peripheral blood wasobtained and peripheral blood mononuclear cells were separated bycentrifugation. 4-1 BB expression was assessed on CD4+CD25+CD127− Tregcells, CD4+ non-Treg cells and CD8+ effector T cells by flow cytometry.Top panels show representative histograms with 4-1BB expression intumour tissue (solid black), blood (dashed grey) and ascites (dashedblack) from the same patient. Isotype control depicted in solid grey.Lower panel shows 4-1 BB expression on T cell subsets from differenttissue samples. Data points represent individual patients/donors withn=11 for healthy PBMCs, n=20 for ascites, n=9 for tumour and n=5 forpatient blood. FIG. 3C: Samples of freshly excised cutaneous squamouscell carcinoma (SCC) and normal skin were obtained from patients atsurgery. Samples were minced and digested before separation with adensity gradient. Matched peripheral blood was obtained and peripheralblood mononuclear cells were separated by centrifugation. Cells werestained for 4-1BB and staining detected by flow cytometry. Top panelsshow representative histograms with 4-1BB staining shown as openhistograms; tumour tissue (solid black), blood (dashed grey), normalskin (dashed black) and isotype control (solid grey). Lower panel shows4-1 BB expression on T cell subsets from different tissue samples. Datapoints represent 10 individual patients.

FIG. 4 . The primary mechanism of anti-4-1 BB mAb therapy in solidtumours is dependent on antibody isotype and FcγR availability. FIG. 4A:Groups of 3-4 WT, FcγRIIB KO or γ chain KO BALB/c mice received werechallenged with 5×104 CT26 cells s.c. on day 0. When tumours werepalpable mice received anti-4-1 BB mIgG1, mIgG2a or PBS control i.v.followed by 3 further administrations i.p. every other day (200 μg finaldose). Mice were sacrificed on day 13 and spleen and tumour analysed byflow cytometry. Data show the frequency of Foxp3+ cells within the CD4+population in the tumour (left panel) or in matched spleens (rightpanel). Data are representative of two independent experiments. FIG. 4B:Mice were treated as in (A) and CD8+, Ki67+ T cells enumerated andplotted as fold change compared to control. FIG. 4C: Groups of WT, γchain KO, or FcγR null mice (γ chain KO×FcγRIIB KO), γ chain KO orFcγRIIB KO BALB/c mice were challenged with 5×104 CT26 cells and treatedwith anti-4-1 BB mAb as in (A). Tumour growth was monitored and miceculled when mean tumour area exceeded 225 mm2. Data are expressed astumour area (mm2) on the days after tumour challenge as indicated, eachline represents an individual mouse. Panels on the right show percentagesurvival to the humane end-point. Data represent examples of at least 2experiments where n=5 mice per group. FIG. 4D: CFSE labelled targetmurine splenic T cells opsonised with anti-4-1 BB mIgG1, mIgG2a orcontrol mAb were co-cultured with wild type (solid bars) or FcgRIIB KO(open bars) mBMDM and then assessed for phagocytosis. (E) (left panel)CFSE labelled target human T cells opsonised with anti-human 4-1 BBhIgG1 mAb clones SAP3-6, B15-B02 (also denoted 005-B102) or control wereco-cultured with hMDM and then assessed for ADCP. (right hand panel)Level of phagocytosis plotted in relation to 4-1 BB expression level asdetermined by flow cytometry. In all cases phagocytosis is plotted as %of double positive macrophages.

FIG. 5 . Scheduled administration of disparate anti-4-1 BB or scheduledcombination with anti-PD-1 mAb enhances anti-tumour activity. FIG. 5A:Groups of age and sex matched BALB/c mice were challenged with 5×104CT26 s.c. on day 0. When tumours were palpable mice received anti-4-1 BB(LOB12.0) mIgG1, mIgG2a, concurrent mIgG1 and mIG2a or PBS control i.v.followed by 3 further administrations i.p. every other day (200 μg finaldose). For scheduled administration mIgG2a was given i.v. and then mIgG1given i.p. 4 days later. Tumour growth was monitored and mice culledwhen mean tumour area exceeded 225 mm². Data are expressed as theaverage tumour area (mm2) on the days after tumour challenge asindicated. Data presented is combined from two independent experimentswhere n=10 mice per group. FIG. 5B: Mice were challenged with CT26tumour and then given monotherapy as in FIG. 5A or scheduledcombinations of anti-4-1 BB mIgG1 or mIgG2a and/or anti-PD-1 rIgG1 (WT)or its deglycosylated form. For combinations anti-4-1 BB mAb wereadministered i.v. when tumours were first palpable and then anti-PD-1given i.p. 4 days later. Tumour growth was monitored and data plotted asin FIG. 5A. Data represent examples of at least 2 independentexperiments where n=4 or 5 mice per group. FIG. 6 . Fc engineeredanti-4-1BB mIgG2a/h2B possesses dual activity and delivers augmentedcancer therapy. FIG. 6A: nrCE-SDS profiles of anti-4-1 BB (LOB12.0)mIgG2a, mIgG2a/h2 and “skewed” mIgG2a/h2B. FIG. 6B: Splenocytes fromC57131/6 mice were incubated with 0.01 μg/ml anti-CD3 and the indicatedconcentrations of either anti-4-1 BB mIgG1, mIgG2a or mIgG2a/h2B asindicated. Incorporation of [3H]-thymidine was measured during the last16 hours of a 72 hour culture. FIG. 6C: CFSE labelled target murinesplenic T cells opsonised with anti-4-1 BB mIgG2a, mIgG2a/h2B or controlmAb were co-cultured with wild type mBMDM and then assessed forphagocytosis. Phagocytosis is plotted as % of double positivemacrophages. FIG. 6D: Groups of age and sex matched C57131/6 mice werechallenged with 5×105 EG7 s.c. on day 0. On days 3, 5 and 7 micereceived 200 μg mAb or PBS control i.p. as indicated. On day 20 tumourswere harvested and TIL enumerated by flow cytometry. n=4 mice per group.(E) Mice were set up as in (D) and tumour growth was monitored and miceculled when mean tumour area exceeded 400 mm2. Data represent examplesof at least 2 independent experiments where n=5 mice per group.

FIG. 7 . Anti-4-1 BB mAb characterisation. FIG. 7A: Surface plasmonresonance analysis of anti-4-1 BB (clone LOB12.0) mIgG1, mIgG2a and theparental rIgG2a binding to mouse FcγRI, IIB, III and IV. Recombinant,soluble FcγR protein (0, 6, 23, 94, 375, 1500 nM) was passed over 4-1-BBmAb immobilized at 5000 RU. Sensorgrams are shown. FIG. 7B: A human cellline stably transfected with a construct encoding the extracellular andtransmembrane region of murine 4-1 BB was incubated with anti-4-1 BB ofmIgG1, mIgG2a isotype or with the parental rIgG2a mAb at a range ofconcentrations prior to staining with a PE-labelled secondary antibody.Data show mean fluorescence intensity at each concentration as apercentage of maximum. FIG. 7C: Rat anti-4-1 BB was mixed with mousemIgG1 or mIgG2a anti-4-1 BB mAb at the concentrations indicated, priorto incubation with a murine 4-1BB transfected cell line. Rat mAb bindingwas detected with an anti-rat secondary antibody and data are expressedas mean fluorescence intensity of the rat anti-4-1BB antibody relativeto the concentration of competitive mouse anti-4-1 BB.

FIG. 8 . Anti-tumour efficacy of anti-4-1BB mIgG2a mAb is dependent uponCD8+ T cells. Groups of BALB/c mice were treated, or not, with 500 μg ofa CD8-depleting antibody on days −1, 1 and 4 relative to challenge with5×10⁴ CT26 cells s.c. on day 0. Anti-41 BB mIgG2a mAb was administeredon day 6 i.v., and on days 8, 10 and 12 i.p, to a final total dose of200 μg. Tumour sizes were recorded and mice culled when mean tumourdiameter reached 15 mm. Data show tumour area (mm²) on the daysindicated after tumour challenge with each line representing anindividual mouse. (n=5/group)

FIG. 9 . Primary in vivo expansion of OT-I cells in response to OVA andanti-4-1BB mAb. FIG. 9A: Groups of 3 wild type or FcγRIIB−/− micereceived 2×10⁵ OT-1 cells i.v., followed 24 hours later (day 0) by i.p.injection of 0.5 mg OVA and 200 μg mIgG1 or mIgG2a anti-4-1 BB. Controlmice received OVA alone. Blood samples were taken to measure circulatingSIINFEKL tetramer+CD8+ cells over the course of the response, expressedas a % (mean±SEM) of total CD8+ cells. Data are representative of 2experiments. FIG. 9B: Groups of 5 C57BL/6 mice were injected with2.5×10⁵ B16/BL6 cells i.d. on day 0 prior to receiving 1×10⁶ irradiatedFVAX cells i.d. on the opposite flank on days 3, 6 and 9. Concurrentwith FVAX injection mice received either PBS, 100 μg anti-CTLA-4 (clone9D9) or anti-CTLA-4 and 300 μg anti-4-1 BB antibodies as indicated i.p.Percentage survival to the humane end point is shown.

FIG. 10 . Anti-PD-1 mAb characterisation. FIG. 10A: Surface plasmonresonance analysis of anti-PD-1 (clone EW1-9) rIgG1 (solid black) andrIgG1 deglycosylated (solid grey) binding to mouse FcγRI, IIB, III andIV. PD-1 mAb (500 nM) was passed over recombinant FcγR-his protein (1000RU) (R&D Systems) captured onto a CM5 chip with an anti-histidine mAb(GE Healthcare). Sensorgrams are shown with 0 nM curve subtracted. FIG.10B: Analysis demonstrating that anti-PD-1 mAb bind to PD-1 and blockPD-L1 binding. Anti-PD-1 rIgG1 (solid black), rIgG1 deglycosylated(solid grey) or buffer (dashed black) was passed over recombinantPD-1-his (R&D Systems) (2000 RU) captured onto a CM5 chip with ananti-histidine mAb. At the timepoint indicated by the arrow recombinantPD-L1-Fc (R&D Systems) was passed over to demonstrate binding to PD-1and blockade by anti-PD1.

FIG. 11 . Anti-4-1BB mIgG2a/h2B FcγR binding. Surface plasmon resonanceanalysis of anti-4-1 BB (clone LOB12.0) mIgG2a and mIgG2a/h2B binding tomouse FcγRI, IIB, III and IV. Recombinant, soluble FcγR protein (0, 6,23, 94, 375, 1500 nM) was passed over 4-1 BB mAb immobilized at 5000 RU.Sensorgrams are shown.

FIG. 12 shows binding titration curves for HDLM2 cells.

FIG. 13 shows ligand blocking.

FIG. 14 shows the results of in vitro assays with ADCC for 4-1 BB+IVACD4s in the left panel and CD8 T cell proliferation in the right panel.

FIG. 15 shows binding to in vitro activated human CD4+ cells.

FIG. 16 shows cyon cross-reactivity on activated CD4+ T cells.

FIG. 17 shows ligand blocking.

FIG. 18 shows ADCC on T cells and demonstrates that several mAbs inducesignificant ADCC on OX40 expressing CD4+ T cells. Figure show mean of 5experiments. Campath is used as positive ctrl and Yervoy as comparator.

FIG. 19 shows results from proliferation assays in vitro.

FIG. 20 demonstrates agonistic activity in vivo using h OX40 KI/OT1transfer model for different antibodies.

FIG. 21 shows a table summarizing the characteristics of some of theantibodies described herein.

FIG. 22 shows Treg cells and effector cells from different compartmentsin human and demonstrates that Tregs in tumor tissue and/or in closevincinity of tumor tissue has clearly distinct potential targetexpression profiles compared to peripheral Tregs.

FIG. 23 shows receptor expression on Treg cells from different organs inmouse.

FIG. 24 shows receptor expression on Treg cells compared to other celltypes in mouse.

EXAMPLES

Specific, non-limiting examples which embody certain aspects of theinvention will now be described.

Examples Relating to Sequential Administration

Results

Therapeutic Activity of Anti-4-1BB mAb is Determined by Isotype

We and others have previously established the dependence ofimmunostimulatory mAb activity targeting TNFR superfamily members oncross-linking provided by the inhibitory FcγRIIB. To establish if thisrequirement similarly applied to anti-4-1 BB we generated mIgG1 andmIgG2a chimeric versions of the rIgG2a anti-4-1BB mAb (LOB12.0 generatedin-house (16)) as previously described for other mAb specificities(17-19). The nucleotide sequences encoding LOB12.0 mIgG1 heavy chain isshown in SEQ. ID. NO: 179, and the corresponding amino acid sequence isshown in SEQ ID NO: 180. The nucleotide sequences encoding LOB12.0mIgG2a heavy chain is shown in SEQ. ID. NO: 181, and the correspondingamino acid sequence is shown in SEQ ID NO: 182. Analysis by surfaceplasmon resonance and flow cytometry established that these mAbpossessed an expected mFcγR binding profile, with mIgG2a having a highactivatory to inhibitory FcγR ratio (A:I) and conversely mIgG1 a low A:I(FIG. 7A, (19, 20)); both mAb retained equivalent 4-1 BB specificity andbinding (FIGS. 7B and 7C). We then assessed the therapeutic potential ofthese mouse anti-4-1 BB mAb in three different established solid tumourmodels using the CT26 colon carcinoma (FIG. 1A) and NXS2 neuroblastoma(FIG. 1B). In marked contrast to our studies with anti-CD40 (18, 19, 21)and published reports with other agonistic anti-TNFR superfamily mAbtargeting DR5 (22, 23), for anti-4-1 BB, high A:I ratio mIgG2a mAb gaveconsiderable therapeutic benefit (80% long term survival in all models)while the low A:I ratio mIgG1 version was largely ineffective (0-20%survival). Notably, although it was the mIgG2a mAb which was protectivein these settings its therapeutic effect was still dependent upon CD8+ Tcells (FIG. 8 ) and led to long term productive anti-tumour immunity, asdetermined by tumour re-challenge experiments. These results suggestthat the protective effect of mIgG2a anti-4-1BB is mediated through anadaptive anti-tumoural immune response, but that this mAb utilisesmolecular mechanisms occurring in an FcγRIIB-independent manner, incontrast to anti-CD40 mAb.

Immunostimulatory Activity of Anti-4-1BB is Optimal with Mouse IgG1Isotype

Given the results obtained in our tumour models and previous studiesdemonstrating a critical role for CD8+ T cells in mediating the effectsof anti-4-1 BB mAb, we sought to establish the isotype-dependence ofanti-4-1 BB mAb activity on T cell populations in vitro and in vivo.Using an in vitro T cell co-stimulation assay (FIG. 2A) only mIgG1, butnot mIgG2a, (same antibodies as used above) demonstrated agonisticactivity. This is in keeping with other published results (18, 19). Thecostimulatory activity of mIgG1 was independent of Treg cells in the Tcell culture assay, suggesting that this anti-4-1 BB mAb mediates itseffects through targeting 4-1 BB on effector T cells. Finally, thecostimulatory activity of mIgG1 was abolished by the addition of mIgG2a,demonstrating that both mAb variants bind with similar avidity andcompete for binding to 4-1 BB on effector T cells (FIG. 2B). These invitro results were confirmed using an in vivo immunisation model withthe model antigen OVA in both an endogenous (FIG. 2C) and an OT1 T celltransfer setting (FIG. 8A). In this context the superior agonisticactivity of mIgG1 was dependent upon the inhibitory FcγRIIB (FIG. 2C,FIG. 9A) as previously shown for anti-CD40 mAb (18, 19, 24, 25).Finally, in two immunisation models (NXS2 peptide and B16-sFlt3L-Ig;FIG. 2D and FIG. 9B, respectively) the mIgG1 and mIgG2a isotypeantibodies were equally therapeutic (FIG. 2D and FIG. 9B). Of note, theefficacy of mIgG1, but not IgG2a, was abolished in the absence ofvaccination, confirming that mIgG1, but not mIgG2a, is operating througha mechanism dependent on immune activation, and likely FcγRIIBcross-linking (FIG. 2D).

4-1BB is expressed on intra-tumoural Treg cells in mouse tumour modelsand human cancer patients Having established that anti-4-1 BB mIgG2a ismore active than mIgG1 in treating mice with established tumours, but inthese mice mIgG2a lacks the ability to deliver co-stimulatory activity,we looked for alternative mechanisms that could explain itsimmunomodulatory effects. 4-1 BB mRNA and protein are preferentiallyexpressed in Treg cells compared to resting effector T cells (14, 26,27) its expression is further upregulated following activation of Tregcells (27, 28) and very recently has been shown to be upregulated, atleast at the transcriptional level, in intratumoral Treg in human solidcancers (29, 30). We therefore examined the possibility that anti-4-1 BBmIgG2a, which possesses a high A:I FcγR binding profile could potentiatean anti-tumour response via deletion of Treg cells. We began byconfirming the presence of 4-1 BB on Treg cells in two murine tumourmodels CT26 (FIG. 3A) and NXS2 and found that 4-1 BB was expressed on asubstantial proportion of tumour-infiltrating Tregs and only a smallminority of effector T cells. Furthermore, only a small fraction ofsplenic Treg cells expressed 4-1 BB. In order to confirm that theseobservations were potentially translatable to humans at the proteinlevel, we determined by flow cytometry whether 4-1 BB was present onintratumoural Tregs in patients with ovarian cancer and squamous cellcarcinoma. It can be seen in FIG. 3B and FIG. 3C that 4-1 BB was foundon CD4+Foxp3+Treg cells but not on effector CD4+ or CD8+ T cells intumours and that 4-1 BB was expressed at lower levels on Tregs isolatedfrom healthy PBMC, matched blood, ascites or normal skin.

The Role of FcγR in Mediating the Anti-Tumour Activity of Anti-4-1 BBmAb

Having established that intratumoural Treg express 4-1 BB we used theCT26 tumour model to determine the potential role for and relativedepleting capacity of anti-4-1 BB mAb. Our data demonstrate that inwild-type mice the mIgG2a mAb efficiently deleted intratumoural Tregs,whilst the mIgG1 variant was ineffective (same antibodies as used above(FIG. 4A). This depletion effect was restricted to the tumour anddependent upon expression of the common γ chain, a crucial component ofactivatory FcγR complexes. Furthermore, in FcγRIIB knockout mice thedepleting activity of the mIgG1 mAb was enhanced to similar levels as tothat of the mIgG2a, demonstrating that the depletion efficiency of thesemAb is intimately linked to their FcγR A:I ratio and that depletionpotency can be manipulated through changes in FcγR expression. We nextsought to determine if we could observe activation of tumourinfiltrating CD8 T cells in these mice and observed that despite thelack of efficacy of the mIgG1 mAb in WT tumour bearing miceadministration of anti-4-1 BB mIgG1 mAb led to a clear and significantincrease in proliferation of CD8 T cells as monitored by Ki-67positivity (FIG. 4B). While the mIgG2a isotype also induced an increasein CD8 activation this was significantly less than the mIgG1. These datalikely demonstrate the dominant role of Treg in the CT26 tumour modeland suggest that inducing CD8 responses with mIgG1 in wild-type micewithout removing Treg suppression is insufficient to induce a productiveanti-tumour response.

As anti-4-1 BB mIgG2a was efficient in mediating depletion ofintra-tumoural Treg cells in a manner dependent on the expression ofactivatory FcγR, we reasoned that the absence of activatory FcγR wouldbe detrimental for the therapeutic effects of this mAb. Surprisingly,however, in the CT26 tumour model (FIG. 4C), anti-4-1 BB mIgG2a retainedantitumour activity in the absence of activatory FcγR, suggesting thatTreg cell depletion may not fully account for its therapeutic activity.In contrast to the minimal effects on anti-4-1 BB mIgG2a efficacy, therewas a substantial improvement in the ability of anti-4-1 BB mIgG1 topromote anti-tumour immunity in the absence of activatory FcγR (2/5 inCT26). Given the FcγR binding profiles demonstrated for mIgG1 and mIgG2amAb (FIG. 7 ), these findings suggest that in the absence of competitivebinding of mAb to activatory FcγR, there is productive engagement ofFcγRIIB by both mIgG1 and mIgG2a, thus allowing optimal crosslinking ofmAb to deliver costimulation. This notion is further supported by theobserved T cell activation of mIgG2a in the FcRg KO animals in the OVAmodel (FIG. 2C). In keeping with the enhanced Treg depleting activity ofmIgG1 in FcγRIIB KO mice (FIG. 4A) when therapies were carried out inFcγRIIB KO mice the mIgG1 isotype mAb demonstrated enhanced andequivalent activity to mIgG2a. These results coupled with theobservation that in the absence of all FcγR, neither mAb produced anytherapeutic activity (FIG. 4C) support the importance of efficient,non-competing FcγR engagement for optimal in vivo activity.

We next sought to formally demonstrate the depleting capacity ofanti-4-1 BB mAb using both mouse and human targets and effectors invitro. Using WT mouse bone marrow derived macrophages and 4-1BBexpressing T cell targets we observed that mIgG2a induced effectivephagocytosis of target cells and the mIgG1 mAb was ineffective (FIG.4D). In agreement with our in vivo depletion results (FIG. 4B) andtherapeutic responses (FIG. 4C), when FcγRIIB KO macrophages were usedas effectors a significant increase in mIgG1 mediated phagocytosis wasobserved in line with levels obtained with mIgG2a and WT effectors. Wethen confirmed the translational potential of our findings in a fullyhuman system using human targets and monocyte derived macrophageeffectors. In this system we found that two different huIgG1 anti-human4-1 BB clones (SAP3-6 and 005-B02) could mediate effective phagocyticclearance (FIG. 4E). Finally, we sought to confirm that it was the levelof 4-1 BB expression rather than the cell type per se that dictated theefficacy of depletion. We did this using both human (FIG. 4E) and mouse(data not shown) in vitro generated macrophages and target cells withvarying levels of 4-1 BB expression and found a direct correlationbetween 4-1 BB expression and the efficiency of target cell depletion.This supports the notion that it is the high level of 4-1 BB expressionon Treg in the tumour microenvironment that makes them a good target andthat lower expressing CD8 cells are likely spared.

Scheduled Administration of Treg Depleting and Immunomostimulatory mAbLeads to Enhanced Anti-Cancer Therapy

Our results demonstrating that the therapeutic activity of isotypevariants of anti-4-BB mAb occurs via different mechanisms indicated apotential for combined use to enhance therapeutic effects. However,since depletion of Treg cells (mIgG2a) and delivery of costimulation (mIgG1) both relied on engagement of FcγRs, and appeared to do so in acompetitive manner, we speculated that sequential rather than concurrentadministration might be optimal. We therefore compared the therapeuticeffect following concurrent and sequential administration of anti-4-1 BBmIgG2a and mIgG1 mAb. (same antibodies as used above) As previouslyobserved the mIgG2a, but not mIgG1, variant was active as single agent.Concurrent administration of mIgG2a and mIgG1 anti-4-1 BB mAb resultedin reduced therapeutic efficacy as indicated by increased tumour size(FIG. 5A) and reduced number of tumour free mice (FIG. 5B) compared tomIgG2a single agent treatment. In marked contrast, sequential deliveryof first mIgG2a, to delete Treg cells, followed by agonistic mIgG1 toprovide costimulation, improved both tumour growth inhibition andenhance the number of tumour free mice compared with single agenttreatment with either antibody variant alone (FIGS. 5A and B). Thesefindings demonstrated that therapeutic efficacy of FcγR-dependentimmunomodulatory mAb can be optimised by sequential administration.Importantly, our findings also indicated that Treg depletion may havebroad utility to improve on immune-stimulatory antibodies beyondanti-4-1BB, especially when used in an FcgR-non competing manner.

Next, we therefore investigated the therapeutic potential of combiningTreg depleting anti-4-1 BB with clinically validated immune agonistanti-PD1. We reduced the dosing of mAb to obtain suboptimal monotherapyand then combined isotype optimal anti-4-1 BB mIgG2a sequentially withan FcγR null binding deglycosylated (31) variant anti-PD-1 blockingantibody (FIGS. 10A and 10B) mimicking the lack of/poor FcγR-engagementof clinically validated anti-PD-1 antibodies nivolumab andpembrolizumab. This combination produced a significant increase intherapy leading to 80% long term responders compared with 20-25 withmonotherapies (FIG. 5C). Notably, the combination of suboptimal isotypesof mAb did not lead to any enhancement of responses demonstrating thatfor optimal combination therapies it is vital to understand the isotypeand scheduling requirement of each component of any combination.

Anti-4-1 BB mIgG2a/h2B Engineered to Possess Dual Activity DeliversAugmented Cancer Therapy

Having demonstrated that better responses can be achieved throughoptimal combination of Treg depletion and agonism/release of immunesuppression than through either mechanism alone we sought to demonstratethat it is possible to deliver these multiple mechanisms through theengineering of a single mAb. Given our observations that mAb mediatedTreg depletion and immunostimulatory agonism have differential andcompeting FcγR requirements we sought to capitalise on our previousfinding that the human IgG2 hinge region is able to provide anti-TNFRsuperfamily member mAb with FcγR independent agonistic properties (25).Here, we cloned the human IgG2 region into the murine mIgG2a constantregions of anti-4-1 BB as detailed previously (25) and then skewed thehinge to the agonism enhanced ‘B’ form to make anti-4-1 BB mIgG2a/h2B(FIG. 6A). The nucleotide sequences encoding LOB12.0 mKappa is shown inSEQ. ID. NO: 183, and the corresponding amino acid sequence is shown inSEQ ID NO: 184. The nucleotide sequences encoding LOB12.0HuIgGhinge2.mIgG2aFc (mIgG2a/h2B) is shown in SEQ. ID. NO: 185, and thecorresponding amino acid sequence is shown in SEQ ID NO: 186. Thenucleotide sequences encoding LOB12 human kappa is shown in SEQ. ID. NO:187, and the corresponding amino acid sequence is shown in SEQ ID NO:188. When tested in vitro for T cell proliferation mIgG2a/h2B hadsignificantly enhanced agonistic activity compared to mIgG2a parent(FIG. 6B), despite an unchanged FcγR binding profile (FIG. 11 ). Despitethis enhanced agonistic activity the engineered mAb also retained strongphagocytic potential in vitro using BMDM and 4-1BB expressing targetcells (FIG. 6C) demonstrating that we had generated a reagent with bothagonistic and depleting potential without competing FcγR requirements.Finally, we compared this mAb with the parental mIgG2a in the EG7 tumourmodel and found that the dual activity mIgG2a/h2B had equally potentTreg depleting capacity to the parental mIgG2a but now also possessedmarked CD8 stimulating capability leading to an enhanced CD8/Treg ratio(FIG. 6D). This enhanced dual activity mAb also demonstrated greatertherapeutic potential curing 100% of mice treated compared to 60% withthe standard mIgG2a (FIG. 6E). These data demonstrate for the first timethat a single mAb can be engineered to optimally mediate depletion andagonism and through this enhanced dual activity deliver better therapy.

Discussion

It has been established in a variety of in vitro and in vivo models thatanti-TNFR superfamily mAb require efficient cross-linking to inducetheir agonistic effects and for most mAb this is best provided byinhibitory FcγR engagement (8, 9, 18, 19, 23, 32, 33). Despite thesefindings, it is not clear whether such agonistic engagement is the mainmechanism of action that contributes to the therapeutic activity ofthese mAb in a solid tumour setting. We have investigated this questionusing mIgG2a and mIgG1 isotype anti-4-1 BB mAb, which have a high andlow activatory:inhibitory FcγR ratio, and consequently good depletingand agonistic potential, respectively (10).

We found using two different solid tumour models in different wild typestrains of mice that mIgG2a mAb produced substantial therapeutic effectswhereas mIgG1 was largely ineffective (FIG. 1A, FIG. 1B). These resultsare in marked contrast to the agonistic activity of these mAb on CD8+ Tcells, where mIgG1 was more effective (FIG. 2A, FIG. 2B and FIG. 9A).Notably in contrast to previous publications with anti-CD40 mAb,anti-4-1 BB mIgG2a is not without T cell agonistic activity in vivo,suggesting that 4-1 BB may possess a lower crosslinking threshold forsignalling than CD40 (18, 19). The mIgG2a dependent therapeutic activitydisplayed in these different tumour models suggested that therapy waslikely mediated by an effector cell dependent depletion effect. None ofthe tumours used were 4-1 BB positive meaning this could not be a directtumour targeting effect as seen for anti-CD20 mAb (34).

Given the recent findings that mAb targeting CTLA-4, OX40 and GITR areable to mediate therapy through intratumoural T_(reg) depletion (5-7) weexamined 4-1 BB expression in these models and found that 4-1 BB wasupregulated specifically on intra-tumoural Treg cells (FIG. 3A).Importantly for the potential translation of these findings to humans wefound that 4-1 BB demonstrated restricted expression on intratumouralTreg cells in patients with both ovarian cancer and squamous cellcarcinoma (FIG. 3B and FIG. 3C, respectively) supporting the therapeuticpotential of this mechanistic approach in patients. Furthermore, mIgG2adepleted this suppressive population in an activatory FcγR dependantmanner, whilst mIgG1 had little effect (FIG. 4A). In keeping with therequirement for a high activatory to inhibitory FcR engagement forproductive depletion, when these experiments were carried out in FcγRIIBKO mice mIgG1 became comparable to mIgG2a for its depleting capacityboth in vivo (FIG. 4A) and in vitro (FIG. 4D).

Although Treg depletion was the most effective mechanism of action for4-1 BB Ab in these models, we postulated that in the absence ofcompetition for binding with activatory FcγR these mAb may produce atherapeutic effect through their agonistic function. We tested thispotential using the CT26 model and found that in the absence ofactivatory FcγR, mIgG1 mAb did indeed become therapeutic (FIG. 4C). Itwas also notable, and in keeping with our contention that 4-1 BB has arelatively low threshold for cross-linking in vivo, that in the absenceof activatory FcγR mIgG2a also retained activity. In agreement with theenhanced Treg depleting activity of mIgG1 in FcγRIIB KO mice (FIG. 4Aand FIG. 4C) when therapies we carried out in FcγRIIB KO mice the mIgG1isotype mAb demonstrated enhanced and equivalent activity to mIgG2a.Furthermore, neither mAb was able to protect mice in the absence of FcγR(FIG. 4C) demonstrating both agonistic and depletion mechanisms to beFcγR dependent.

The fact that anti-4-1 BB mAb could be therapeutic using two separatemechanisms, given the provision of the appropriate FcγR, suggests thatboth mechanisms could be engaged if mAb were administered sequentially.Indeed this was found to be the case when mIgG2a was given first todelete Treg cells and then mIgG1 given to deliver an agonistic signal(FIG. 5A and FIG. 5B). Importantly, if the mAb were administeredsimultaneously then little therapeutic effect was evident. Theseobservations support the hypothesis that simultaneous engagement ofthese two FcγR dependent mechanisms through the engagement of a singleantigen may not be possible but that temporal, as shown here, orpotentially spatial (intratumour versus systemic) separation of thesemAb may facilitate their combined efficacy.

In order to further demonstrate the likely isotype and schedulingrequirements for anti-4-1 BB mAb in patients, where clinical resultssuggest combination approaches are likely to be required, weinvestigated different mAb combinations with anti-PD-1. In this settingwe found that isotype optimal versions of both anti-4-1 BB and anti-PD-1produced a significant combination effect leading to cures in 80% ofmice treated in marked contrast to monotherapies 20-25% cures andisotype suboptimal combination.

In the clinic there has been much interest in targeting 4-1 BB usingagonistic antibodies. However, our data show that only around 1% of CD8+or CD4+ T cells at a tumour site express 4-1 BB. Furthermore, recentfindings indicate that only around 10% of CD3+CD8+ cells infiltratingthe tumour site in patients with melanoma express 4-1BB, although theseare enriched for tumour-reactive clones (35). Thus, our current findingthat anti-4-1 BB can be used to deplete Tregs to release animmunotherapeutic response suggests that this strategy may beparticularly appealing in patients. Clinical studies with other putativeTreg-depleting immunotherapeutics (e.g. anti-OX40 and anti-CTLA-4) lookpromising (5, 36, 37) and further confirm the potential of a Tregdepleting anti-4-1 BB mAb in patients.

Currently two fully humanised anti-4-1 BB mAbs are in development;urelumab (BMS-663513), an IgG4 antibody manufactured by Bristol-MyersSquibb, and PF-05082566, a fully humanised IgG2 produced by Pfizer. Thusfar PF-05082566 has proven safe causing only grade 1 toxicities inpatients (38) whereas urelumab caused adverse effects in 15% of patientsincluding increased liver enzymes, pruritis and diarrhea (39). Despitetheir promising safety profiles, neither urelumab or PF-05082566 arepredicted to strongly bind FcγRIIB calling into question whether eitherantibody will prove effective in patients (40). Recent data from ourgroup show that a human IgG2 antibody targeting 4-1 BB can act as asuperagonist independent of FcγRs and it remains possible thatPF-05082566 might act in a similar manner (25). Herein presented data,showing improved efficacy of Treg deleting compared with immune agonistvariant anti-4-1 BB antibodies, and selective intratumoral 4-1 BBexpression on Treg compared with CD8 effector cells, support developmentof human therapeutic anti-4-1 BB IgG1 isotype antibodies selected forcapacity for Treg depletion (40). It was recently demonstrated that suchTreg deleting antibodies may synergize to boost responses, and helpovercome resistance, to checkpoint blockade (50).

Our findings to this point support the contention that immunomodulatorymAb can harness multiple mechanisms of action for therapy and weconsidered the possibility of whether a single antibody could beengineered to carry out both depletion and agonism optimally. Given ourdata demonstrating the competing FcγR requirements for these mechanismsin vitro and in vivo it seemed unlikely that engineering a mAb topossess enhanced activatory and inhibitory FcγR engagement would workgiven that any one mAb can only engage a single FcγR at a time. Giventhese potential limitations we generated a mIgG2a mAb with optimaldepleting capacity to incorporate the hIgG2 hinge region which we skewedto the agonism optimal ‘B’ form. We hypothesised that this mAb would beable to perform both functions and found this to be the case both invitro (FIGS. 6B and C) and in vivo (FIG. 6D) and that this led toenhance therapy in a solid tumour model (FIG. 6E). These results havedirect implications for the administration of existing andin-development immunomodulatory mAb and for the design and developmentof future reagents and strategies for their use.

SEQUENCESSEQ ID NO: 179-nucleotide sequence encoding LOB12.0 mIgG1 heavy chainAAGCTTCAGGACCTCACCATGGAGATCTGGCTCAGCTTGGTTTTCCTTGTCCTTTTCATAAAAGGTGTCCAGTGTGAGGTGCAGCTGGTGGAGTCTGGTGGAGGCTTAGTGCAGCCTGGAAGGTCCCTGAAACTCTCCTGTGCAGCCTCAGGATTCACTTTCAGTAACTTTGGCATGGCCTGGGTCTGCCAGGCTCCAACGACGGGGCTGGAGTGGGTCGCAACCATTAGTTATGATGGTACTGACAGTTACTATCGAGACTCCGTGAAGGACCGATTCACTATCTCCAGAGATAATGCAAAAAGCACCCTATACCTGCAAATGGACAGTCTGAGGTCTGAGGACACGGCCGCTTATTACTGTGTAAGACATGAGGATGTATACTACGGAATGGGGTACTTTGATCACTGGGGCCAAGGAGTACTAGTCACAGTCTCCTCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGTTCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCCCACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGGGATTGTGGTTGTAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTCATCTTCCCCCCAAAGCCCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTAGACATCAGCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGTGCACACAGCTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCTCAGTCAGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAATGCAGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGGCAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGATGGCCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCTGAAGACATTACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCCCATCATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGAAGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTGCACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAATGAGAATTCSEQ ID NO: 180-amino acid sequence of LOB12.0 mIgG1 heavy chain. The underlinedsequence denotes leader sequence.MEIWLSLVFLVLFIKGVQCEVQLVESGGGLVQPGRSLKLSCAASGFTFSNFGMAWVCQAPTTGLEWVATISYDGTDSYYRDSVKDRFTISRDNAKSTLYLQMDSLRSEDTAAYYCVRHEDVYYGMGYFDHWGQGVLVTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGKSEQ ID NO: 181-nucleotide sequence encoding LOB12.0 mIgG2a heavy chain.AAGCTTCAGGACCTCACCATGGAGATCTGGCTCAGCTTGGTTTTCCTTGTCCTTTTCATAAAAGGTGTCCAGTGTGAGGTGCAGCTGGTGGAGTCTGGTGGAGGCTTAGTGCAGCCTGGAAGGTCCCTGAAACTCTCCTGTGCAGCCTCAGGATTCACTTTCAGTAACTTTGGCATGGCCTGGGTCTGCCAGGCTCCAACGACGGGGCTGGAGTGGGTCGCAACCATTAGTTATGATGGTACTGACAGTTACTATCGAGACTCCGTGAAGGACCGATTCACTATCTCCAGAGATAATGCAAAAAGCACCCTATACCTGCAAATGGACAGTCTGAGGTCTGAGGACACGGCCGCTTATTACTGTGTAAGACATGAGGATGTATACTACGGAATGGGGTACTTTGATCACTGGGGCCAAGGAGTACTAGTCACAGTCTCCTCAGCCAAAACGACAGCCCCATCGGTCTATCCACTGGCCCCTGTGTGTGGAGATACAACTGGCTCCTCGGTGACTCTAGGATGCCTGGTCAAGGGTTATTTCCCTGAGCCAGTGACCTTGACCTGGAACTCTGGATCCCTGTCCAGTGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACCCTCAGCAGCTCAGTGACTGTAACCTCGAGCACCTGGCCCAGCCAGTCCATCACCTGCAATGTGGCCCACCCGGCAAGCAGCACCAAGGTGGACAAGAAAATTGAGCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCcaaagatcaaggatgtactcatgatctccctgagccccatagtcacatgtgtggtggtggatgtgagegaggatgacccagatgtccagatcagetggtttgtgaacaacgtggaagtaCaCacAGCTCAGACACAAACCCATAGAGAGGATtaCaACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCttcTCCcggaCTCCgGGTAAATGAGAATTCSEQ ID NO: 182-amino acid sequence of LOB12.0 mIgG2a heavy chain. The underlinedsequence denotes leader sequence.MEIWLSLVFLVLFIKGVQCEVQLVESGGGLVQPGRSLKLSCAASGFTFSNFGMAWVCQAPTTGLEWVATISYDGTDSYYRDSVKDRFTISRDNAKSTLYLQMDSLRSEDTAAYYCVRHEDVYYGMGYFDHWGQGVLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKSEQ ID NO: 183-nucleotide sequence encoding LOB12.0 mKappa.AAGCTTCAGGACCTCACCATGGCTGCACTACAACTCTTAGGGCTGCTGCTGCTCTGGCTCCCAGCCATGAGATGTGACATCCAGATGACCCAGTCTCCTTCATTCCTGTCTGCATCTGTGGGAGACAGAGTCACTCTCAACTGCAAAGCAAGTCAGAATATTAACAAGTACTTAGACTGGTATCAGCAAAAGCTGGGTGAAGCTCCCAAACTCCTGATGTATAATACAAACAGTTTGCATACGGCAATCCCGTCAAGGTTCAGTGGCAGTGGATCTGGTTCTGATTTCACACTTACCATAAGCAGCCTGCAGCCTGAAGATGTTGCCACATATTTCTGCTTTCAGCATAGCAGTGGGTGGACGTTCGGTGGAGGCACCAAGCTGGAATTGAAACGTACGgatgctgcaccaactgtatccatcttcccaccatccagtgagcagttaacatctggaggtgcctcagtcgtgtgcttcttgaacaacttctaccccaaagacatcaatgtcaagtggaagattgatggcagtgaacgacaaaatggcgtcctgaacagttggactgatcaggacagcaaagacagcacctacagcatgagcagcaccctcacgttgaccaaggacgagtatgaacgacataacagctatacctgtgaggccactcacaagacatcaacttcacccattgtcaagagcttcaacaggaatgagtgttaggaattcSEQ ID NO: 184-amino acid sequence of LOB12.0 mKappa. The underlined sequencedenotes leader sequence.MAALQLLGLLLLWLPAMRCDIQMTQSPSFLSASVGDRVTLNCKASQNINKYLDWYQQKLGEAPKLLMYNTNSLHTAIPSRFSGSGSGSDFTLTISSLQPEDVATYFCFQHSSGWTFGGGTKLELKRTDAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNECSEQ ID NO: 185-nucleotide sequence encoding LOB12.0 HuIgGhinge2.mIgG2aFc(mIgG2a/h2B).AAGCTTCAGGACCTCACCATGGAGATCTGGCTCAGCTTGGTTTTCCTTGTCCTTTTCATAAAAGGTGTCCAGTGTGAGGTGCAGCTGGTGGAGTCTGGTGGAGGCTTAGTGCAGCCTGGAAGGTCCCTGAAACTCTCCTGTGCAGCCTCAGGATTCACTTTCAGTAACTTTGGCATGGCCTGGGTCTGCCAGGCTCCAACGACGGGGCTGGAGTGGGTCGCAACCATTAGTTATGATGGTACTGACAGTTACTATCGAGACTCCGTGAAGGACCGATTCACTATCTCCAGAGATAATGCAAAAAGCACCCTATACCTGCAAATGGACAGTCTGAGGTCTGAGGACACGGCCGCTTATTACTGTGTAAGACATGAGGATGTATACTACGGAATGGGGTACTTTGATCACTGGGGCCAAGGAGTACTAGTcaccgtctcctcagcctccACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCAGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGacagttGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCcaaagatcaaggatgtactcatgatctccctgagccccatagtcacatgtgtggtggtggatgtgagcgaggatgacccagatgtccagatcagctggtttgtgaacaacgtggaagtaCaCacAGCTCAGACACAAACCCATAGAGAGGATtaCaACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCttcTCCcggaCTCCgGGTAAATGAGAA TTCSEQ ID NO: 186-amino acid sequence of LOB12.0 HuIgGhinge2.mIgG2aFc(mIgG2a/h2B). The underlined sequence denotes leader sequence.MEIWLSLVFLVLFIKGVQCEVQLVESGGGLVQPGRSLKLSCAASGFTFSNFGMAWVCQAPTTGLEWVATISYDGTDSYYRDSVKDRFTISRDNAKSTLYLQMDSLRSEDTAAYYCVRHEDVYYGMGYFDHWGQGVLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKSEQ ID NO: 187-nucleotide sequence encoding LOB12 human kappa.AAGCTTCAGGACCTCACCATGGCTGCACTACAACTCTTAGGGCTGCTGCTGCTCTGGCTCCCAGCCATGAGATGTGACATCCAGATGACCCAGTCTCCTTCATTCCTGTCTGCATCTGTGGGAGACAGAGTCACTCTCAACTGCAAAGCAAGTCAGAATATTAACAAGTACTTAGACTGGTATCAGCAAAAGCTGGGTGAAGCTCCCAAACTCCTGATGTATAATACAAACAGTTTGCATACGGCAATCCCGTCAAGGTTCAGTGGCAGTGGATCTGGTTCTGATTTCACACTTACCATAAGCAGCCTGCAGCCTGAAGATGTTGCCACATATTTCTGCTTTCAGCATAGCAGTGGGTGGACGTTCGGTGGAGGCACCAAGCTGGAATTGAAACGTACggtgGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTGAgaattcSEQ ID NO: 188-amino acid sequence of LOB12 human kappa. The underlined sequencedenotes leader sequence.MAALQLLGLLLLWLPAMRCDIQMTQSPSFLSASVGDRVTLNCKASQNINKYLDWYQQKLGEAPKLLMYNTNSLHTAIPSRFSGSGSGSDFTLTISSLQPEDVATYFCFQHSSGWTFGGGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Methods

Animals and cells. Mice were bred and maintained in local facilities.Genetically altered strains used were OT1 TCR transgenic C57BL/6 mice(from Dr. Matthias Merken-schlager, Imperial College, London, U.K.),Foxp3-GFP, γ chain KO, FcγRIIB KO and FcγR null (γ chain KO×FcγRIIB KO).Mice were obtained by crossbreeding with genotypes confirmed bypolymerase chain reaction (PCR) and/or flow cytometry. The CT26 coloncarcinoma (16), NXS2 neuroblastoma (41), B16 Flt3vax melanoma (42) andEG7 thymoma (43) models have all been described previously.

Immunotherapy. CT26—Groups of age and sex matched WT, γ chain KO,FcγRIIB KO or FcγR null (γ chain KO×FcγRIIB KO) BALB/c mice werechallenged with 5×10⁴ CT26 s.c. on day 0. When tumours were palpablemice received mAb or PBS control i.v. followed by 3 furtheradministrations i.p. every other day (200 μg final dose unless otherwiseindicated). Where CD8+ T cells were depleted, 0.5 mg of anti-CD8(YTS169) was administered i.p. on days −1, +1, and +4 as previouslydescribed (44) prior to administration of tumour and mAb. NXS2— Groupsof age and sex matched NJ mice were challenged with 2×10⁶ NXS2 cellss.c. on day 0 and received antibody/peptide vaccine as specified inindividual experiments. All antibodies were given i.p. in PBS. TyrosineHydroxylase (FETFEAKI) and control (SIINFEKL car FEANGNLI) peptides inPBS were emulsified in equal volumes of incomplete Freund's adjuvant(IFA) before intradermal injection. Tumor sizes in all models wereregularly monitored by caliper and mice culled when cross-sectional areaexceeded 225 mm², EG7—Groups of age and sex matched C57BL/6 werechallenged with 5×10⁵ EG7 cells s.c on day 0. On days 3, 5 and 7 micereceived 200 μg mAb or PBS control i.p. as indicated. Survival period tothe humane end point were plotted using the Kaplan-Meier method withanalysis for significance by the log-rank test using GraphPad Prism 6.0for Windows (GraphPad Software Inc, La Jolla, Calif.).

Antibodies and reagents. Anti-41BB (clone LOB12.0) mAb mIgG1, mIgG2a andmIgG2a huIgG2 hinge (mIgG2a/h2B) isotypes were constructed as previouslydescribed (18, 25; antibodies as described above). Anti-CD8 (YTS169) wasproduced in house. Anti-mouse PD-1 (EW1-9) mAb rIgG1 was raised usingconventional hybridoma technology after immunisation of Wistar rats withrecombinant mouse PD-1 (Leu25 Gln167) Fc fusion protein (RnD Systems).Spleens from immunised rats or mice were fused with NS-1 myeloma cellsand plates screened by ELISA and flow cytometry. mAbs were initiallyscreened and cells in positive wells were cloned twice and expanded inculture for IgG production. Antibodies were produced from hybridoma orCHOK1 cells and purified on Protein A with purity assessed byelectrophoresis (Beckman EP system; Beckman Coulter, Buckinghamshire,UK) and lack of aggregation by SEC HPLC. All preparations were endotoxinlow (<1 ng endotoxin/mg) as determined using the Endosafe-PTS portabletest system (Charles River Laboratories, L'Arbresie, FR). Anti-CTLA-4(9D9) was purchased from Bio X Cell. Anti-PD-1 de-gly was produced bytreating EW1-9 with 0.05 U of PNGaseF/μg of antibody. N-Glycosidase F(PNGaseF) was obtained from Promega (V483A). Samples were kept at 37° C.overnight. De-glycosylation was confirmed either by EP or SPR analysis.Purification of antibody from enzyme was achieved through size exclusionchromatography using Sephadex™200. Peptides (SIINFEKL, FETFEAKI andFEANGNLI) were obtained from Peptide Protein Research Ltd.

In vitro T cell proliferation. Spleens from Foxp3-GFP mice were sortedto exclude GFP+ cells (−Treg cells; 99% of Treg cells removed) or nullsorted and plated at 1×10⁵ cells/well with 0.1 μg/ml anti-CD3 and arange of anti-4-1 BB mAb concentrations as indicated. 1 μCi/well[³H]-thymidine was added 56 hours later and plates harvested after afurther 16 hours culture.

Endogenous OVA-specific immune responses. Mice were immunised on Day 0with 5 mg OVA (Sigma) and 200 μg mAb as specified in the description ofthe figures. The endogenous OVA specific CD8+ T cell expansion inperipheral blood was monitored over time and analysed by flow cytometryas described previously (18).

Lymphocyte isolation. Mouse—Mice challenged with CT26 or EG7 had theirtumours excised and digested with 0.5 Wu/ml Liberase DL (Roche) and 50μg/ml DNaseI (Roche) for 20 mins at 37° C. Cells were then passedthrough a 100 μm cell strainer and used for assays directly or tumourinfiltrating lymphocytes were isolated using percoll gradient of 40% and70%. Human—Ascitic fluid was assessed as single cell suspension that hadbeen isolated. Ovarian tumour samples were obtained from patientsundergoing surgery at the Department of Obstetrics and Gynaecology atSkánes University Hospital. The material was cut into small pieces andincubated in R10 with DNase I (Sigma) and Liberase™ (Roche Diagnostics)for 20 min at 37° C. Remaining tissue was mechanically dissociated and,together with the cell suspension, passed through a 70 μm cell strainer.Samples of freshly excised cutaneous squamous cell carcinoma (cSCC) andnormal skin were obtained from patients undergoing surgery at theDermatology Department, University Hospital Southampton NHS FoundationTrust, as approved by the South Central Hampshire B National ResearchEthics Service Committee (reference number 07/H0504/187). Samples wereminced and treated with 1 mg/ml collagenase IA (Sigma) and 10 μg/mlDNAse I (Sigma) in RPMI medium (Gibco) at 37° C. for 1.5 hours beforestraining through a 70 μm cell filter (BD) and centrifugation (600×g, 20minutes) over an Optiprep (Axis-Shield) density gradient. Matchedperipheral blood samples were obtained and peripheral blood mononuclearcells were separated by centrifugation over Lymphoprep (Axis-Shield) at600×g for 30 minutes.

Flow cytometry. Mouse—Cell surface staining: Isolated lymphocytes werewashed and incubated with antibody in the dark for 30 minutes on ice inPBS+1% BSA (Sigma) and the cells washed once with PBS/1% BSA. Afterstaining, samples were fixed using Erythrolyse Red Blood cell lysisbuffer (AbD SeroTec). Samples were washed once with PBS/1% BSA, and runon either a BD FACSCanto II or FACSCalibur and the data analysed usingFCS Express. Intracellular staining: After surface staining cells werefixed and stained intracellularly using the anti-Mouse/Rat Foxp3Staining Set (BD Biosciences). Antibodies were anti-CD4 eF450 (GK1.5),anti-CD8-APC-eF780 (53-6.7), anti-Foxp3 APC (FJK-16), anti-4-1-BB(17-B5) (all eBioscience), anti-Ki67 APC (B56) (BD Biosciences) orisotype controls. Human—Before staining with relevant antibodies, cellsfrom ovarian cancer patients were incubated for 10 min with 10 mg/mlKIOVIG (Baxalta). Cell viability: Cells were stained with either fixableeFluor780 Live/Dead stain (eBioscience) or aqua live/dead viabilitystain (Invitrogen) at 4° C. in PBS. Cell surface staining: antibodieswere incubated with cells in the dark for 30 minutes at 4° C. in PBS+1%BSA (Sigma)+10% FCS (Gibco). Intracellular staining was with a Foxp3staining buffer set (eBioscience). Cells were analysed by flow cytometryusing a BD FACSAria or BD FACSVerse. Fluorophore conjugated antibodiesagainst the following cell markers were used: Ovarian-CD4-6V510(RPA-T4), CD25-BV421 (M-A251), anti-CD127-FITC (HIL-7R-M21), CD8-APC(RPA-T8), 411313-PE (4134-1), mouse IgG2a isotype, κ control-PE(G155-178; all from BD Biosciences); SCC− CD3-APC-Cy7, CD4-FITC or PerCPCy5.5, CD8-PE Cy7 (all Biolegend), 4-1BB-PE and Foxp3-APC (botheBioscience).

Antibody Dependent Cellular Phagocytosis. ADCP assays were performed asdescribed previously with mouse (17, 45) or human macrophages (18, 46).Briefly, bone marrow derived macrophages (BMDM) were generated from thefemurs of C57BL/6 mice and cultured in complete RPMI containing 20% L929supernatant. Alternatively, human monocyte derived macrophages (hMDMs)were generated from PBMCs and cultured in complete RPMI containing M-CSF(in house). Target cells were CFSE-stained (5 μM) then opsonised withantibody before being co-cultured with macrophages for −1 h. Macrophageswere stained with CD16-APC or F4/80-APC and samples assessed for thepercentage of double positive (CFSE/APC) macrophages by flow cytometry.

Statistical analyses. Unpaired Students t-test analyses of data wereperformed or for tumour therapy experiments the survival periods to thehumane end point were plotted using the Kaplan-Meier method withanalysis for significance by the log-rank test. All statistical analyseswere carried out using GraphPad Prism 6.0 for Windows (Graph PadSoftware Inc, La Jolla, Ca). Significance was accepted when p<0.05.

Surface Plasmon Resonance. Analyses of anti-41 BB mAb and soluble FcγRinteractions were assayed using a Biacore T100 (GE Healthcare LifeSciences, Buckinghamshire, UK). Antibodies or BSA as a control wereimmobilized at 5000 resonance units [RU]) to the flow cells of CM5sensor chips (GE Healthcare Life Sciences, Buckinghamshire, UK) bystandard amine coupling according to the manufacturer's instructions.Soluble FcγR (R&D Systems, Abingdon, U.K.) were injected through theflow cells at 1500, 375, 94, 23, 6, and 0 nM in HBS-EP+ running buffer(GE Healthcare Life Sciences, Buckinghamshire, UK) at a flow rate of 30μl/min. Soluble Fc receptor was injected for 2 min, and dissociation wasmonitored for 5 min. Background binding to the control flow cell wassubtracted automatically. Affinity constants were derived from the databy equilibrium binding analysis as indicated using Biacore Bioevaluationsoftware (GE Healthcare Life Sciences, Buckinghamshire, UK).

In vitro binding assays. Karpas-299 cells stably transduced with atail-less form of murine 4-1BB (pTL) (47) were incubated with theconcentrations of anti-4-1 BB mAb indicated at 4° C. for 20 mins priorto washing and staining with a PE-labelled anti-mouse or PE-labelledanti-rat secondary antibody (both Jackson labs). No staining wasobserved to Karpas-299 cells stably expressing an empty vector control(data not shown). For the competitive binding assay, 0.1 μg/ml parentalrat anti-4-1 BB mAb was mixed with graded concentrations of either mIgG1or mIgG2a versions of anti-4-1 BB as indicated prior to incubation withKarpas-299 pTL cells. Cells were washed and stained with anAPC-conjugated and mouse-adsorbed donkey anti-rat secondary antibody;the secondary antibody did not bind to either mIgG1 or mIgG2a. Flowcytometric analysis was performed using a BD FACS Canto II and FACS Divasoftware.

OVA-specific immune responses. Splenocytes from OTI transgenic mice wereharvested and washed. Approximately 2×10⁵ OVA-specific CD8 T cells werethen transferred into recipient mice by tail vein injection. Thefollowing day mice were immunised with OVA (Sigma) as described forindividual experiments. OTI expansion in peripheral blood was analysedby flow cytometry as described previously (18). Results at the peak ofthe response are shown (4-5 days post immunisation).

Tumour challenge. B16-sFlt3L-Ig (FVAX)—Groups of C57BL/6 mice werechallenged with 2.5×10⁴ B16/BL6 cells intra-dermally on day 0. On days3, 6 and 9 mice received 1×10⁶ irradiated FVAX cells i.d. on theopposite flank and either PBS, 100 μg anti-CTLA-4 (clone 9D9) oranti-CTLA-4 and 300 μg anti-4-1 BB antibodies as indicated i.p. also onday 3, 6 and 9 based on our previously published protocol (48).

Examples Relating to Specific 4-1 Bb Antibodies and Specific OX40Antibodies

Material and Methods

Animals and Cells

Mice were bred and maintained in local facilities in accordance withhome office guidelines. Ten to twelve week-old female BALB/c and C57 bl6mice were supplied by Taconic (Bomholt, Denmark) and maintained in localanimal facilities. For the xenograft studies with primary tumor cells,6-8 week-old female BALB/c and C57 bI6 mice were grafted with syngeneictumor cell lines CT26 and TH03, respectively.

Clinical Samples

Ethical approval for the use of clinical samples was obtained by theEthics Committee of Skåne University Hospital. Informed consent wasprovided in accordance with the Declaration of Helsinki. Samples wereobtained through the Department of Gynocology and Department of Oncologyat Skåne University Hospital, Lund. Ascitic fluid was assessed as singlecell suspensions that had been isolated. Tumor material was cut intosmall pieces and incubated in R10 with DNase I (Sigma Aldrich) andLiberase™ (Roche Diagnostics) for 20 min at 37° C. Remaining tissue wasmechanically crashed and, together with the cell suspension, passedthrough a 70 μm cell strainer. Cells isolated from ascitic fluid andtumors were stained. Data acquisition was performed using FACSVerse anddata analyzed using FlowJo.

Cell Culture

Cell culture was performed in supplemented RPMI (RPMI containing 2 mMglutamine, 1 mM pyruvate, 100 IU/ml penicillin and streptomycin and 10%FBS (GIBCO by Life Technologies). Human peripheral CD4+ T-cells werepurified by negative selection using MACS CD4 T-cell isolation kit(Miltenyi Biotec, UK).

Antibodies and Reagents

The following antibodies and reagents were used: purified anti-CD3(UCHT1; R&D Systems); purified anti-CD28 (CD28.2; BioLegend); KIOVIG(Baxalta, Lessines, Belgium); Fixable Viability Dye eFluor780(eBioscience, San Diego, Calif.). Cell Trace CFSE (dissolved in DMSO)and Propidium Iodide were from Life Technologies (Carlsbad, Calif.).

Following reagents were used to stain human lymphocytes: CD4-BV510(RPA-T4), CD25-BV421 (M-A251), anti-CD127-FITC (HIL-7R-M21), Ox40-PE(ACT35), 41BB-PE (4B4-1), ICOS-PE (DX29), GITR-PE (621), PD-1-PE (MIH4),CTLA-4-PE (BN13), CD4-APC (RPAT4), CD8-APC (RPA-T8), mouse IgG1, Kisotype control-PE (MOPC-21), mouse IgG2a isotype, κ control-PE(G155-178), mouse IgG2b isotype, K control-PE (27-53; all from BDBiosciences); TNFRII-PE (FAB226P; R&D Systems).

Following reagents were used to stain mouse lymphocytes: CD4-BV510(RM4-5), CD25-BV421 (7D4), CD8-Alexa 488 (53-6.7; BD), Ox40, 41 BB,TNFRII, ICOS, GITR, PD-1, CTLA4, FITC negative control (scFv, in-housegenerated BioInvent).

Flow Cytometry

Flow cytometry was performed according to standard procedures. Deadcells (identified as propidium iodide+ or using Fixable Viability DyeeFluor780) and cell aggregates were excluded from all analyses.Fluorescently conjugated mAb were purchased from BD Biosciences,eBiosciences, BioLegend or made in-house. Data acquisition was performedon a FACSVerse (BD Biosciences, Franklin Lakes, N.J.) and analyzed withFlowJo software (Tree Star, Ashland, Oreg.). For Genexpression analysiscells were sorted using a FACSAria (BD Biosciences). Staining within-house generated scFv was detected with in-house Alexa 647 labeled,deglycosolated anti-His Tag antibody (AD1.1.10, R&D Systems).CFSE-labeling of T cells was performed according to manufacturer'sinstructions.

Antibody Dependent Cellular Cytotoxicity (ADCC)

ADCC assays were performed in two ways: a) ADCC assays were performedusing an NK-92 cell line stably transfected to express the CD16-158Vallele together with GFP (purchased from Conkwest, San Diego, Calif.)24. CD4+ target T cells were isolated from peripheral blood of healthydonors using CD4+ T cell isolation kit (Miltenyi Biotec). Cells werestimulated for 2d with CD3/CD28 dynabeads (Life Technologies, ThermoFisher) and 50 ng/ml rh IL-2 (R&D Systems) at 37° C. Target cells werepre-incubated with mAB at 0.1-10 μg/ml for 30 min at 4° C. prior tomixing with NK cells. The cells were incubated for 4 h in RPMI1640+GlutaMAX medium (Invitrogen) containing 10 mM HEPES buffer, 1 mMsodium Pyruvate and 10% FBS low IgG at a 2:1 effector:target cell ratio.Lysis was determined by flow cytometry. Briefly, at the end of theincubation, the cell suspension was stained with BV510-conjugatedanti-CD4 together with 10 nM SYTOX Red dead cell stain (Invitrogen) orFixable Viability Dye eFluor780 (eBioscience) for 20 min in the dark at4° C. and the cells were then analyzed using a FACSVerse (BDBiosciences). b) Target cells were labelled with calcein AM, followed bythe addition of diluting concentrations of Ab. Target cells werecocultured with human PBMCs at a 50:1 E:T ratio for 4 h at 37° C. Theplate was centrifuged at 400 3 g for 5 min to pellet the cells, and thesupernatant was transferred to a white 96-well plate. Calcein releasewas measured using a Varioskan (Thermo Scientific) using an excitationwavelength of 485 nm and emission wavelength, 530 nm. The percentage ofmaximal release was calculated as follows: % max release=(sample/tritontreated)*100.

Antibody Dependent Cellular Phagocytosis (ADCP)

Target cells were labelled with 5 mM CFSE for 10 min at room temperaturebefore washing in complete media. CFSE-labelled targets were thenopsonized with diluting concentrations of Ab before coculturing at a 1:5E:T ratio with BMDMs in 96-well plates for 1 h at 37° C. BMDMs were thenlabelled with anti-F4/80—allophycocyanin for 15 min at room temperatureand washed with PBS twice. Plates were kept on ice, wells were scrapedto collect BMDMs, and phagocytosis was assessed by flow cytometry usinga FACSCalibur (BD) to determine the percentage of F4/80+CFSE+ cellswithin the F4/80+ cell population.

T-Cell Proliferation Assay

The agonistic activity of antibodies was tested using two protocols: a)Antibodies were cross-linked with F(ab′)2 goat anti-human IgG, Fcgfragment specific or F(ab′)2 goat anti-mouse IgG, Fcg fragment specificin a molar ratio IgG:F(ab)2=1.5:1 for 1 h at RT. 1×105 MACS-purifiedhuman CD4+ T-cells were CFSE-labelled and stimulated with plate-boundanti-CD3 (0.5 μg/ml) and 4 μg/ml of soluble, cross-linked IgG for 3 daysat 37° C. before analysis. b) Cell culture was in RPMI 1640 media(Gibco™) supplemented with 10% foetal calf serum, glutamine (2 mM),pyruvate (1 mM), penicillin, and streptomycin (100 IU/mL) at 37° C. in5% CO2. Fresh PBMCs were labelled with 2 mM carboxyfluoresceinsuccinimidyl ester (CFSE). PBMCs were then cultured in a 24-well plateat 1×107 cells/mL as described by Römer et al (51) for 48 hours prior tomAb stimulation assays. For PBMC stimulation, round-bottomed 96-wellplates were wet-coated with 0.01 μg/mL of OKT3 antibody (in-house) inPBS for 4 hours after which excess antibody was discarded and the plateswere washed with PBS. 1×105 PBMCs/well were transferred to the platesand stimulated with 5 μg/mL of test mAb (anti-4-1BB, anti-OX40 mAb). Onday 4 or day 5 post-stimulation, cells were labelled with anti-CD8-APC(BioLegend), and anti-CD4-PE (in-house) and proliferation was assessedby CFSE dilution on a FACSCalibur (BD Biosciences).

Ligand Blocking ELISA

Human receptors (hox40, R&D Systems; h41 BB, in-house produced) werecoated to 96-well plates (Lumitrac 600 LIA plate, Greiner) at 1pmole/well. After washing, mAbs (10 μg/ml-0.01 μg/ml) were allowed tobind for 1 hour. Ligands were added at 5 nM (hox40-L, h41 BB-L; R&DSystems) and the plates were further incubated for 15 minutes. Afterwashing, bound ligand was detected with biotinylated antibodies(anti-hox40-L, anti-h41 BB-L; R&D Systems) followed by Streptavidin-HRP(Jackson ImmunoResearch) with intermediate washing. Super Signal ELISAPico (Thermo Scientific) was used as substrate and the plates wereanalyzed using Tecan Ultra Microplate reader.

Microarray Analysis

CD4+CD25+ target cells and CD4+CD25− non-target cells were sorted fromlymph nodes of tumor-bearing mice (CT26 and TH03). CD3− non-target cellswere sorted from spleens of healthy 057/B16 and Balb/c mice. CD8+ Tcells were isolated from spleens of healthy Balb/c mice. RNA from allthe samples was prepared with RNA isolation Midi kit from Macherey-Nagel(Dueren, Germany) according to manufactures' instructions. Isolated RNAwas amplified and prepared for hybridization to the Affymetrix MouseGene 2.0 ST Array at Swegene Centre for Integrative Biology at LundUniversity (SCIBLU), Sweden. Data analysis was performed at SCIBLUaccording to standard methods.

The results of the above assays and the characteristics of theantibodies studied are shown in FIGS. 12-24 .

EMBODIMENTS

In the following an itemized listing of different embodiments of theinvention is presented:

1. A Treg depleting antibody molecule for use in the treatment of cancerwherein the Treg depleting antibody molecule is administeredsequentially with an immunostimulatory antibody molecule with the Tregdepleting antibody molecule being administered prior to administrationof the immunostimulatory antibody molecule.

2. A Treg depleting antibody for use according to embodiment 1, whereinsaid immunostimulatory antibody molecule is a CD8 activating and/or CD8boosting antibody molecule.

3. A Treg depleting antibody molecule for use according to embodiment 1or 2, wherein the cancer is a solid tumour.

4. A Treg depleting antibody molecule for use according to embodiment 3,wherein the solid tumour is selected from the group consisting ofsarcomas, carcinomas, lymphomas and ovarian cancer.

5. A Treg depleting antibody molecule for use according to embodiment 3,wherein the solid tumour is squamous cell carcinoma (SCC), thymoma,neuroblastoma or ovarian cancer

6. A Treg depleting antibody molecule for use according any one of theembodiments 1-5, wherein said Treg depleting antibody molecule and/orsaid immunostimulatory antibody molecule is selected from the groupconsisting of a full-size antibody, a Fab, a Fv, an scFv, a Fab′, and a(Fab′)₂.

7. A Treg depleting antibody molecule for use according any one of theembodiments 1-6, wherein said Treg depleting antibody molecule and/orsaid immunostimulatory antibody molecule is a human or humanizedantibody.

8. A Treg depleting antibody molecule for use according to any one ofthe embodiments 1-7, wherein said Treg depleting antibody molecule is ahuman IgG1 antibody.

9. A Treg depleting antibody molecule for use according to any one ofthe embodiments 1-8, wherein said Treg depleting antibody molecule is ahuman IgG1 antibody molecule engineered for improved binding to at leastone activatory FcγR.

10. A Treg depleting antibody molecule for use according to any one ofthe embodiments 1-9, wherein said Treg depleting antibody molecule isselected from antibody molecules binding specifically to a targetbelonging to the tumour necrosis factor receptor superfamily (TNFRSF).

11. A Treg depleting antibody molecule for use according to embodiment10, wherein said Treg depleting antibody molecule is an antibodymolecule that binds specifically to a target selected from the groupconsisting of 4-1 BB, OX40, and TNFR2.

12. A Treg depleting antibody molecule for use according to any one ofthe embodiments 1-9, wherein said Treg depleting antibody molecule is anantibody molecule that binds specifically to a target selected fromGITR, ICOS, CTLA-4 and CD25.

13. A Treg depleting antibody molecule for use according to embodiment11, wherein said Treg depleting antibody molecule is an anti-4-1 BBmonoclonal antibody molecule.

14. A Treg depleting antibody for use according to embodiment 13,wherein the Treg depleting antibody molecule is selected from the groupconsisting of antibody molecules comprising 1-6 of the CDRs selectedfrom SEQ. ID. NOs: 1-6; 1-6 of the CDRs selected from SEQ. ID. NOs:9-14; 1-6 of the CDRs selected from SEQ. ID. NOs: 17-22; 1-6 of the CDRsselected from SEQ. ID. NOs: 25-30; 1-6 of the CDRs selected from SEQ.ID. NOs: 33-38; 1-6 of the CDRs selected from SEQ. ID. NOs: 41-46; 1-6of the CDRs selected from SEQ. ID. NOs: 49-54; 1-6 of the CDRs selectedfrom SEQ. ID. NOs: 57-62; 1-6 of the CDRs selected from SEQ. ID. NOs:65-70; 1-6 of the CDRs selected from SEQ. ID. NOs: 153-158; and 1-6 ofthe CDRs selected from SEQ. ID. NOs: 163-168.

15. A Treg depleting antibody for use according to embodiment 14,wherein the Treg depleting antibody molecule is selected from the groupconsisting of antibody molecule comprising SEQ. ID. NOs: 1-6, SEQ. ID.NOs: 9-14, SEQ. ID. NOs: 17-22, SEQ. ID. NOs: 25-30, SEQ. ID. NOs:33-38, SEQ. ID. NOs: 41-46, SEQ. ID. NOs: 49-54, SEQ. ID. NOs: 57-62,SEQ. ID. NOs: 65-70, SEQ. ID. NOs: 153-158, and SEQ. ID. NOs: 163-168.

16. A Treg depleting antibody for use according to embodiment 14 or 15,wherein the Treg depleting antibody molecule is selected from the groupconsisting of antibody molecules comprising a variable heavy chainselected from the group consisting of SEQ. ID. NOs: 7, 15, 23, 31, 39,47, 55, 63, 71, 159, and 169.

17. A Treg depleting antibody for use according to any one of theembodiments 14-16, wherein the Treg depleting antibody molecule isselected from the group consisting of antibody molecule comprising avariable light chain selected from the group consisting of SEQ. ID. NOs:8, 16, 24, 32, 40, 48, 56, 64, 72, 160, and 170.

18. A Treg depleting antibody for use according to any one of theembodiments 14-17, wherein the Treg depleting antibody molecule isselected from the group consisting of antibody molecule comprising SEQ.ID. NOs: 7 and 8; SEQ. ID. NOs: 15 and 16; SEQ. ID. NOs: 23 and 24; SEQ.ID. NOs: 31 and 32; SEQ. ID. NOs: 39 and 40; and SEQ. ID. NOs: 47 and48; SEQ. ID. NOs: 55 and 56; SEQ. ID. NOs: 63 and 64, SEQ. ID. NOs: 71and 72; SEQ. ID. NOs: 159 and 160; and SEQ. ID. NOs: 169 and 170.

19. A Treg depleting antibody molecule for use according to embodiment11, wherein said Treg depleting antibody is a human anti-OX40 monoclonalantibody molecule.

20. A Treg depleting antibody for use according to embodiment 19,wherein the Treg depleting antibody molecule is selected from the groupconsisting of antibody molecule comprising one or more of the CDRsselected from SEQ. ID. NOs: 73-78, 81-86, 89-94, 97-102 105-110,113-118, 121-126, 129-134, 137-142, 145-150, and 171-176.

21. A Treg depleting antibody for use according to embodiment 20,wherein the Treg depleting antibody molecule is selected from the groupconsisting of antibody molecules comprising SEQ. ID. NOs: SEQ. ID. NOs:73-78, SEQ. ID. NOs: 81-86, SEQ. ID. NOs: 89-94, SEQ. ID. NOs: 97-102,SEQ. ID. NOs: 105-110, SEQ. ID. NOs: 113-118, SEQ. ID. NOs: 121-126,SEQ. ID. NOs: 129-134, SEQ. ID. NOs: 137-142, SEQ. ID. NOs: 145-150 andSEQ. ID. NOs: 177-178.

22. A Treg depleting antibody for use according to embodiment 20 or 21,wherein the Treg depleting antibody molecule is selected from the groupconsisting of antibody molecules comprising a variable heavy chainselected from the group consisting of SEQ. ID. NOs: 79, 87, 95, 103,111, 119, 127, 135, 143, 151, and 177.

23. A Treg depleting antibody for use according to any one of theembodiments 20-22, wherein the Treg depleting antibody molecule isselected from the group consisting of antibody molecules comprising avariable light chain selected from the group consisting of SEQ. ID. NOs:80, 88, 96, 104, 112, 120, 128, 136, 144, 152 and 178.

24. A Treg depleting antibody for use according to any one of theembodiments 20-23, wherein the Treg depleting antibody molecule isselected from the group consisting of antibody molecules comprising SEQ.ID. NOs: 79 and 80; SEQ. ID. NOs: 87 and 88; SEQ. ID. NOs: 95 and 96;SEQ. ID. NOs: 103 and 104; SEQ. ID. NOs: 111 and 112; SEQ. ID. NOs: 119and 120; SEQ. ID. NOs: 127 and 128; SEQ. ID. NOs: 135 and 136; SEQ. ID.NOs: 143 and 144; SEQ. ID. NOs: 151 and 152; and SEQ. ID. NOs: 177 and178.

25. A Treg depleting antibody molecule for use according to any one ofthe embodiments 1-9, wherein said Treg depleting antibody molecule isselected from antibody molecules binding specifically to a targetselected from the group consisting of ICOS, GITR, CTLA-4, CD25, andneuropilin-1.

26. A Treg depleting antibody for use according to any one of theembodiments 1-25, wherein the immunostimulatory antibody molecule is ahuman IgG2 antibody or a human IgG4 antibody molecule.

27. A Treg depleting antibody for use according to embodiment 26,wherein the immunostimulatory antibody molecule is a human IgG2bantibody molecule.

28. A Treg depleting antibody molecule for use according to any one ofthe embodiments 1-27, wherein the immunostimulatory antibody molecule isengineered for enhanced binding to human FcγRIIB over activatory Fcgamma receptors.

29. A Treg depleting antibody molecule for use according to any one ofthe embodiments 1-28, wherein the immunostimulatory antibody molecule isan antibody that binds specifically to a target selected from the groupconsisting of 4-1BB, OX40, ICOS, GITR, CTLA-4 CD25, PD-1 and PDL1.

30. A Treg depleting antibody molecule for use according to embodiment29, wherein the immunostimulatory antibody molecule is an anti-4-1 BBantibody molecule.

31. A Treg depleting antibody molecule for use according to embodiment30, wherein the immunostimulatory antibody molecule is selected from thegroup consisting of antibody molecules comprising one or more of theCDRs selected from SEQ. ID. NOs: 1-6, 9-14, 17-22, 25-30, 33-38, 41-46,49-54, 57-62, 65-70, 153-158 and 163-168.

32. A Treg depleting antibody for use according to embodiment 31,wherein the immunostimulatory antibody molecule is selected from thegroup consisting of antibody molecule comprising SEQ. ID. NOs: 1-6, SEQ.ID. NOs: 9-14, SEQ. ID. NOs: 17-22, SEQ. ID. NOs: 25-30, SEQ. ID. NOs:33-38, SEQ. ID. NOs: 41-46, SEQ. ID. NOs: 49-54, SEQ. ID. NOs: 57-62,SEQ. ID. NOs: 65-70, SEQ. ID. NOs: 153-158 and SEQ. ID. NOs: 163-168.

33. A Treg depleting antibody for use according to embodiment 31 or 32,wherein the immunostimulatory antibody molecule is selected from thegroup consisting of antibody molecules comprising a variable heavy chainselected from the group consisting of SEQ. ID. NOs: 7, 15, 23, 31, 39,47, 55, 63, 71, 159 and 169.

34. A Treg depleting antibody for use according to any one of theembodiments 31-33, wherein the immunostimulatory antibody molecule isselected from the group consisting of antibody molecule comprising avariable light chain selected from the group consisting of SEQ. ID. NOs:8, 16, 24, 32, 40, 48, 56, 64, 72, 160 and 170.

35. A Treg depleting antibody for use according to any one of theembodiments 31-34, wherein immunostimulatory antibody molecule isselected from the group consisting of antibody molecule comprising SEQ.ID. NOs: 7 and 8; SEQ. ID. NOs: 15 and 16; SEQ. ID. NOs: 23 and 24; SEQ.ID. NOs: 31 and 32; SEQ. ID. NOs: 39 and 40; and SEQ. ID. NOs: 47 and48; SEQ. ID. NOs: 55 and 56; SEQ. ID. NOs: 63 and 64, SEQ. ID. NOs: 71and 72, SEQ. ID. NOs: 159 and 160, and SEQ. ID. NOs: 169 and 170.

36. A Treg depleting antibody molecule for use according to embodiment29, wherein the immunostimulatory antibody molecule is an anti-OX40antibody molecule.

37. A Treg depleting antibody molecule for use according to embodiment36 wherein the immunostimulatory antibody molecule is selected from thegroup consisting of antibody molecule comprising one or more of the CDRsselected from SEQ. ID. NOs: 73-78, 81-86, 89-94, 97-102 105-110,113-118, 121-126, 129-134, 137-142, 145-150, and 171-176.

38. A Treg depleting antibody for use according to embodiment 37,wherein the immunostimulatory antibody molecule is selected from thegroup consisting of antibody molecules comprising SEQ. ID. NOs: SEQ. ID.NOs: 73-78, SEQ. ID. NOs: 81-86, SEQ. ID. NOs: 89-94, SEQ. ID. NOs:97-102, SEQ. ID. NOs: 105-110, SEQ. ID. NOs: 113-118, SEQ. ID. NOs:121-126, SEQ. ID. NOs: 129-134, SEQ. ID. NOs: 137-142, SEQ. ID. NOs:145-150, and SEQ. ID. NOs: 171-176.

39. A Treg depleting antibody for use according to embodiment 37 or 38,wherein the immunostimulatory antibody molecule is selected from thegroup consisting of antibody molecules comprising a variable heavy chainselected from the group consisting of SEQ. ID. NOs: 79, 87, 95, 103,111, 119, 127, 135, 143, 151 and 177.

40. A Treg depleting antibody for use according to any one of theembodiments 37-39, wherein the immunostimulatory antibody molecule isselected from the group consisting of antibody molecules comprising avariable light chain selected from the group consisting of SEQ. ID. NOs:80, 88, 96, 104, 112, 120, 128, 136, 144, 152 and 178.

41. A Treg depleting antibody for use according to any one of theembodiments 37-40, wherein the immunostimulatory antibody molecule isselected from the group consisting of antibody molecules comprising SEQ.ID. NOs: 79 and 80; SEQ. ID. NOs: 87 and 88; SEQ. ID. NOs: 95 and 96;SEQ. ID. NOs: 103 and 104; SEQ. ID. NOs: 111 and 112; SEQ. ID. NOs: 119and 120; SEQ. ID. NOs: 127 and 128; SEQ. ID. NOs: 135 and 136; SEQ. ID.NOs: 143 and 144; SEQ. ID. NOs: 151 and 152; and SEQ. ID. NOs: 177-178.

42. A Treg depleting antibody molecule for use according to embodiment29, wherein the immunostimulatory antibody molecule is a human anti-PD1monoclonal antibody molecule, a human anti-PDL1 monoclonal antibodymolecule or a human anti-CTLA-4 monoclonal antibody molecule.

43. A Treg depleting antibody molecule for use according to embodiment42, wherein the wherein the immunostimulatory antibody molecule is ahuman anti-PD1 monoclonal antibody molecule selected from the groupconsisting of nivolumab and pembrolizumab or the anti-PDL1 antibodyatezolizumab or an anti-CTLA-4 antibody selected from the groupconsisting of ipilimumab and tremilimumab.

44. An anti-4-1 BB antibody molecule selected from the group consistingof antibody molecules comprising one or more of the CDRs selected fromSEQ. ID. NOs: 1-6,9-14, 17-22, 25-30, 33-38, 41-46, 49-54, 57-62, 65-70,153-158 and 163-168.

45. An anti-4-1 BB antibody molecule according to embodiment 44 selectedfrom the group consisting of antibody molecule comprising SEQ. ID. NOs:1-6, SEQ. ID. NOs: 9-14, SEQ. ID. NOs: 17-22, SEQ. ID. NOs: 25-30, SEQ.ID. NOs: 33-38, SEQ. ID. NOs: 41-46, SEQ. ID. NOs: 49-54, SEQ. ID. NOs:57-62, SEQ. ID. NOs: 65-70, SEQ. ID. NOs: 153-158, and SEQ. ID. NOs:163-168.

46. An anti-4-1 BB antibody molecule according to embodiment 44 or 45selected from the group consisting of antibody molecule comprising avariable heavy chain selected from the group consisting of SEQ. ID. NOs:7, 15, 23, 31, 39, 47, 55, 63, 71, 159, and 169.

47. An anti-4-1 BB antibody molecule according to any one of theembodiments 44-46 selected from the group consisting of antibodymolecule comprising a variable light chain selected from the groupconsisting of SEQ. ID. NOs: 8, 16, 24, 32, 40, 48, 56, 64, 72, 160, and170.

48. An anti-4-1 BB antibody molecule according to any one of theembodiments 44-47 selected from the group consisting of antibodymolecule comprising SEQ. ID. NOs: 7 and 8; SEQ. ID. NOs: 15 and 16; SEQ.ID. NOs: 23 and 24; SEQ. ID. NOs: 31 and 32; SEQ. ID. NOs: 39 and 40;SEQ. ID. NOs: 47 and 48; SEQ. ID. NOs: 55 and 56; SEQ. ID. NOs: 63 and64; SEQ. ID. NOs: 71 and 72; SEQ. ID. NOs: 159 and 160; and SEQ. ID.NOs: 169-170.

49. An anti-4-1 BB antibody molecule according to any one of theembodiments 44-48 selected from the group consisting of a full-lengthIgG antibody, a Fab, a Fv, an scFv, a Fab′, and a (Fab′)₂.

50. An anti-4-1 BB antibody molecule according to embodiment 49, whereinthe full-length IgG antibody is selected from the group consisting of anIgG1, IgG2, IgG4, and an Fc-engineered variant thereof.

51. An anti-4-1 BB antibody molecule according to any one of theembodiments 44-50, wherein said Treg depleting antibody molecule and/orsaid immunostimulatory antibody molecule is a human or humanizedantibody.

52. An anti-OX40 antibody molecule selected from the group consisting ofantibody molecule comprising one or more of the CDRs selected from SEQ.ID. NOs: 73-78, 81-86, 89-94, 97-102 105-110, 113-118, 121-126, 129-134,137-142, 145-150, and 171-176.

53. An anti-OX40 antibody molecule according to embodiment 52 selectedfrom the group consisting of antibody molecule comprising SEQ. ID. NOs:SEQ. ID. NOs: 73-78, SEQ. ID. NOs: 81-86, SEQ. ID. NOs: 89-94, SEQ. ID.NOs: 97-102, SEQ. ID. NOs: 105-110, SEQ. ID. NOs: 113-118, SEQ. ID. NOs:121-126, SEQ. ID. NOs: 129-134, SEQ. ID. NOs: 137-142, SEQ. ID. NOs:145-150, and SEQ. ID. NOs: 171-176.

54. An anti-OX40 antibody molecule according to embodiment 52 or 53selected from the group consisting of antibody molecule comprising avariable heavy chain selected from the group consisting of SEQ. ID. NOs:79, 87, 95, 103, 111, 119, 127, 135, 143 151 and 177.

55. An anti-OX40 antibody molecule according to any one of theembodiments 52-54 selected from the group consisting of antibodymolecules comprising a variable light chain selected from the groupconsisting of SEQ. ID. NOs: 80, 88, 96, 104, 112, 120, 128, 136, 144,152 and 178.

56. An anti-OX40 antibody molecule according to any one of theembodiments 52-55 selected from the group consisting of antibodymolecules comprising SEQ. ID. NOs: 79 and 80; SEQ. ID. NOs: 87 and 88;SEQ. ID. NOs: 95 and 96; SEQ. ID. NOs: 103 and 104; SEQ. ID. NOs: 111and 112; SEQ. ID. NOs: 119 and 120; SEQ. ID. NOs: 127 and 128; SEQ. ID.NOs: 135 and 136; SEQ. ID. NOs: 143 and 144; SEQ. ID. NOs: 151 and 152;and SEQ. ID. NOs: 177 and 178.

57. An anti-OX40 antibody molecule according to any one of theembodiments 52-56, wherein said Treg depleting antibody molecule and/orsaid immunostimulatory antibody molecule is selected from the groupconsisting of a full-length IgG antibody, a Fab, a Fv, an scFv, a Fab′,and a (Fab′)₂.

58. An anti-OX40 antibody molecule according to embodiment 57, whereinthe full-length IgG antibody is selected from the group consisting of anIgG1, IgG2, IgG4, and an Fc-engineered variant thereof.

59. An anti-OX40 antibody molecule according to any one of theembodiments 52-58, wherein said Treg depleting antibody molecule and/orsaid immunostimulatory antibody molecule is a human or humanizedantibody.

60. An isolated nucleic acid encoding an antibody according to any oneof the embodiments 44-59.

61. A vector comprising the nucleic acid according to embodiment 60.

62. A host cell comprising the vector according to embodiment 61.

63. An antibody according to any one of the embodiments 44-59 for use inmedicine.

64. A pharmaceutical composition comprising an antibody according to anyone of the embodiments 44-59

65. An antibody according to embodiment 63 or a pharmaceuticalcomposition according to embodiment 64 for use in the treatment ofcancer.

66. An antibody or a pharmaceutical composition according to embodiment65, wherein the cancer is a solid tumour.

67. An antibody or a pharmaceutical composition according to embodiment66, wherein the solid tumour is selected from the group consisting ofsarcomas, carcinomas and lymphomas.

68. An antibody or a pharmaceutical composition according to embodiment67, wherein the solid tumour is squamous cell carcinoma (SCC), thymoma,neuroblastoma or ovarian cancer.

69. An antibody according to any one of the embodiments 44-59 or apharmaceutical composition comprising an antibody according to any oneof the embodiments 44-51 and an antibody according to any one of theembodiments 52-59.

70. An antibody according to any one of the embodiments 44-59 or apharmaceutical composition according to embodiment 69, wherein thepharmaceutical composition is for treatment of cancer.

71. An antibody according to any one of the embodiments 44-59 or apharmaceutical composition according to embodiment 70, wherein thecancer is a solid tumour.

72. An antibody according to any one of the embodiments 44-59 or apharmaceutical composition according to embodiment 71, wherein the solidtumour is selected from the group consisting of sarcomas, carcinomas andlymphomas.

73. An antibody according to any one of the embodiments 44-59 or apharmaceutical composition according to embodiment 72, wherein the solidtumour is squamous cell carcinoma (SCC), thymoma, neuroblastoma orovarian cancer.

74. Use of an antibody according to any one of the embodiments 44-59 forthe manufacture of a pharmaceutical composition for use in treatment ofcancer.

75. Use according to embodiment 74, wherein the cancer is a solidtumour.

76. Use according to embodiment 75, wherein the solid tumour is selectedfrom the group consisting of sarcomas, carcinomas and lymphomas.

77 Use according to embodiment 76, wherein the solid tumour is squamouscell carcinoma (SCC), thymoma, neuroblastoma or ovarian cancer.

78. A method for treatment of cancer in a subject, wherein a Tregdepleting antibody molecule is administered to the subject, and whereinthe administration of the Treg depleting antibody molecule issequentially by administration of an immunostimulatory antibodymolecule.

79. The method of embodiment 78, wherein said immunostimulatory antibodymolecule is a CD8 activating and/or CD8 boosting antibody molecule.

80. The method of embodiment 78 or 79, wherein the cancer is a solidtumour.

81. The method of embodiment 80, wherein the solid tumour is selectedfrom the group consisting of sarcomas, carcinomas and lymphomas.

82. The method of embodiment 81, wherein the solid tumour is squamouscell carcinoma (SCC), thymoma, neuroblastoma or ovarian cancer.

83. The method of any one of the embodiments 78-82, wherein said Tregdepleting antibody molecule and/or said immunostimulatory antibodymolecule is selected from the group consisting of a full-length IgGantibody, a Fab, a Fv, an scFv, a Fab′, and a (Fab′)₂.

84. The method of embodiment 83, wherein the full-length IgG antibody isselected from the group consisting of an IgG1, IgG2, IgG4, and anFc-engineered variant thereof.

85. The method of any one of the embodiments 78-84, wherein said Tregdepleting antibody molecule and/or said immunostimulatory antibodymolecule is a human or humanized antibody.

86. The method of any one of the embodiments 78-85, wherein said Tregdepleting antibody molecule is a human IgG1 antibody.

87. The method of any one of the embodiments 78-86, wherein said Tregdepleting antibody molecule is a human IgG1 antibody molecule engineeredfor improved binding to at least one activatory FcγR.

88. The method of any one of the embodiments 78-87, wherein said Tregdepleting antibody molecule is selected from antibody molecules bindingspecifically to a target belonging to the tumour necrosis factorreceptor superfamily (TNFRSF).

89. The method of embodiment 88, wherein said Treg depleting antibodymolecule is an antibody molecule that binds specifically to a targetselected from the group consisting of 4-1 BB, OX40, and TNFR2.

90. The method of embodiment 87, wherein said Treg depleting antibodymolecule is an anti-4-1 BB monoclonal antibody molecule.

91. The method of embodiment 89, wherein the Treg depleting antibodymolecule is selected from the group consisting of antibody moleculescomprising one or more of the CDRs selected from SEQ. ID. NOs: 1-6,9-14, 17-22, 25-30, 33-38, 41-46, 49-54, 57-62, 65-70, 153-158 and163-168.

92. The method of embodiment 91, wherein the Treg depleting antibodymolecule is selected from the group consisting of antibody moleculecomprising SEQ. ID. NOs: 1-6, SEQ. ID. NOs: 9-14, SEQ. ID. NOs: 17-22,SEQ. ID. NOs: 25-30, SEQ. ID. NOs: 33-38, SEQ. ID. NOs: 41-46, SEQ. ID.NOs: 49-54, SEQ. ID. NOs: 57-62, SEQ. ID. NOs: 65-70, SEQ. ID. NOs:153-158, and SEQ. ID. NOs: 163-168.

93. The method of embodiment 91 or 92, wherein the Treg depletingantibody molecule is selected from the group consisting of antibodymolecules comprising a variable heavy chain selected from the groupconsisting of SEQ. ID. NOs: 7, 15, 23, 31, 39, 47, 55, 63, 71, 159 and169.

94. The method of any one of the embodiments 91-93, wherein the Tregdepleting antibody molecule is selected from the group consisting ofantibody molecule comprising a variable light chain selected from thegroup consisting of SEQ. ID. NOs: 8, 16, 24, 32, 40, 48, 56, 64, 72, 160and 170.

95. The method of any one of the embodiments 91-94, wherein the Tregdepleting antibody molecule is selected from the group consisting ofantibody molecule comprising SEQ. ID. NOs: 7 and 8; SEQ. ID. NOs: 15 and16; SEQ. ID. NOs: 23 and 24; SEQ. ID. NOs: 31 and 32; SEQ. ID. NOs: 39and 40; and SEQ. ID. NOs: 47 and 48; SEQ. ID. NOs: 55 and 56; SEQ. ID.NOs: 63 and 64; SEQ. ID. NOs: 71 and 72; SEQ. ID. NOs: 159 and 160; andSEQ. ID. NOs: 169-170.

96. The method of embodiment 89, wherein said Treg depleting antibody isa human anti-OX40 monoclonal antibody molecule.

97. The method of embodiment 96, wherein the Treg depleting antibodymolecule is selected from the group consisting of antibody moleculecomprising one or more of the CDRs selected from SEQ. ID. NOs: 73-78,81-86, 89-94, 97-102 105-110, 113-118, 121-126, 129-134, 137-142,145-150, and 171-176.

98. The method of embodiment 97, wherein the Treg depleting antibodymolecule is selected from the group consisting of antibody moleculescomprising SEQ. ID. NOs: SEQ. ID. NOs: 73-78, SEQ. ID. NOs: 81-86, SEQ.ID. NOs: 89-94, SEQ. ID. NOs: 97-102, SEQ. ID. NOs: 105-110, SEQ. ID.NOs: 113-118, SEQ. ID. NOs: 121-126, SEQ. ID. NOs: 129-134, SEQ. ID.NOs: 137-142, SEQ. ID. NOs: 145-150, and SEQ. ID. NOs: 171-176.

99. The method of any one of the embodiments 96-98, wherein the Tregdepleting antibody molecule is selected from the group consisting ofantibody molecules comprising a variable heavy chain selected from thegroup consisting of SEQ. ID. NOs: 79, 87, 95, 103, 111, 119, 127, 135,143, 151 and 177.

100. The method of any one of the embodiments 96-99, wherein the Tregdepleting antibody molecule is selected from the group consisting ofantibody molecules comprising a variable light chain selected from thegroup consisting of SEQ. ID. NOs: 80, 88, 96, 104, 112, 120, 128, 136,144, 152 and 178.

101. The method of any one of the embodiments 96-100, wherein the Tregdepleting antibody molecule is selected from the group consisting ofantibody molecules comprising SEQ. ID. NOs: 79 and 80; SEQ. ID. NOs: 87and 88; SEQ. ID. NOs: 95 and 96; SEQ. ID. NOs: 103 and 104; SEQ. ID.NOs: 111 and 112; SEQ. ID. NOs: 119 and 120; SEQ. ID. NOs: 127 and 128;SEQ. ID. NOs: 135 and 136; SEQ. ID. NOs: 143 and 144; SEQ. ID. NOs: 151and 152; and SEQ. ID. NOs: 177 and 178.

102. The method of any one of the embodiments 78-87, wherein said Tregdepleting antibody molecule is selected from antibody molecules bindingspecifically to a target selected from the group consisting of ICOS,GITR, CTLA-4, CD25 and neuropilin-1.

103. The method of any one of the embodiments 78-102, wherein theimmunostimulatory antibody molecule is a human IgG2 antibody or a humanIgG4 antibody molecule.

104. The method of embodiment 103, wherein the immunostimulatoryantibody molecule is a human IgG2b antibody molecule.

105. The method of any one of the embodiments 78-104, wherein theimmunostimulatory antibody molecule is engineered for enhanced bindingto human FcγRIIB over activatory Fc gamma receptors.

106. The method of any one of the embodiments 76-105, wherein theimmunostimulatory antibody molecule is an antibody that bindsspecifically to a target selected from the group consisting of 4-1 BB,OX40, ICOS, GITR, CTLA-4 CD25, PD-1 and PDL1.

107. The method of embodiment 106, wherein the immunostimulatoryantibody molecule is an anti-4-1 BB antibody molecule.

108. The method of embodiment 107, wherein the immunostimulatoryantibody molecule is selected from the group consisting of antibodymolecules comprising one or more of the CDRs selected from SEQ. ID. NOs:1-6, 9-14, 17-22, 25-30, 33-38, 41-46, 49-54, 57-62, 65-70, 153-158 and163-168.

109. The method of 108, wherein the immunostimulatory antibody moleculeis selected from the group consisting of antibody molecule comprisingSEQ. ID. NOs: 1-6, SEQ. ID. NOs: 9-14, SEQ. ID. NOs: 17-22, SEQ. ID.NOs: 25-30, SEQ. ID. NOs: 33-38, SEQ. ID. NOs: 41-46, SEQ. ID. NOs:49-54, SEQ. ID. NOs: 57-62, SEQ. ID. NOs: 65-70, SEQ. ID. NOs: 153-158,and SEQ. ID. NOs: 163-168.

110. The method of any one of the embodiments 107-109, wherein theimmunostimulatory antibody molecule is selected from the groupconsisting of antibody molecules comprising a variable heavy chainselected from the group consisting of SEQ. ID. NOs: 7, 15, 23, 31, 39,47, 55, 63, 71, 159 and 169.

111. The method of any one of the embodiments 107-110, wherein theimmunostimulatory antibody molecule is selected from the groupconsisting of antibody molecule comprising a variable light chainselected from the group consisting of SEQ. ID. NOs: 8, 16, 24, 32, 40,48, 56, 64, 72, 160 and 170.

112. The method of any one of the embodiments 107-111, whereinimmunostimulatory antibody molecule is selected from the groupconsisting of antibody molecule comprising SEQ. ID. NOs: 7 and 8; SEQ.ID. NOs: 15 and 16; SEQ. ID. NOs: 23 and 24; SEQ. ID. NOs: 31 and 32;SEQ. ID. NOs: 39 and 40; or SEQ. ID. NOs: 47 and 48; SEQ. ID. NOs: 55and 56; SEQ. ID. NOs: 63 and 64; SEQ. ID. NOs: 71 and 72; SEQ. ID. NOs:159 and 160; and SEQ. ID. NOs: 169 and 170.

113. The method of embodiment 106, wherein the immunostimulatoryantibody molecule is an anti-OX40 antibody molecule.

114. The method of embodiment 113, wherein the immunostimulatoryantibody molecule is selected from the group consisting of antibodymolecule comprising one or more of the CDRs selected from SEQ. ID. NOs:73-78, 81-86, 89-94, 97-102 105-110, 113-118, 121 126, 129-134, 137-142,145-150, and 171-176.

115. The method of embodiment 114, wherein the immunostimulatoryantibody molecule is selected from the group consisting of antibodymolecules comprising SEQ. ID. NOs: SEQ. ID. NOs: 73-78, SEQ. ID. NOs:81-86, SEQ. ID. NOs: 89-94, SEQ. ID. NOs: 97-102, SEQ. ID. NOs: 105-110,SEQ. ID. NOs: 113-118, SEQ. ID. NOs: 121-126, SEQ. ID. NOs: 129-134,SEQ. ID. NOs: 137-142, SEQ. ID. NOs: 145-150, and SEQ. ID. NOs: 171-176.

116. The method of any one of the embodiments 113-115, wherein theimmunostimulatory antibody molecule is selected from the groupconsisting of antibody molecules comprising a variable heavy chainselected from the group consisting of SEQ. ID. NOs: 79, 87, 95, 103,111, 119, 127, 135, 143, 151 and 177.

117. The method of any one of the embodiments 113-116, wherein theimmunostimulatory antibody molecule is selected from the groupconsisting of antibody molecules comprising a variable light chainselected from the group consisting of SEQ. ID. NOs: 80, 88, 96, 104,112, 120, 128, 136, 144, 152 and 178.

118. The method of any one of the embodiments 113-117, wherein theimmunostimulatory antibody molecule is selected from the groupconsisting of antibody molecules comprising SEQ. ID. NOs: 79 and 80;SEQ. ID. NOs: 87 and 88; SEQ. ID. NOs: 95 and 96; SEQ. ID. NOs: 103 and104; SEQ. ID. NOs: 111 and 112; SEQ. ID. NOs: 119 and 120; SEQ. ID. NOs:127 and 128; SEQ. ID. NOs: 135 and 136; SEQ. ID. NOs: 143 and 144; SEQ.ID. NOs: 151 and 152; and SEQ. ID. NOs: 177 and 178.

119. The method of embodiment 106, wherein the immunostimulatoryantibody molecule is human anti-PD1 monoclonal antibody molecule, ahuman anti-PDL1 monoclonal antibody molecule or a human anti-CTLA-4monoclonal antibody molecule.

120. The method of embodiment 119, wherein the wherein theimmunostimulatory antibody molecule is a human anti-PD1 monoclonalantibody molecule selected from the group consisting of nivolumab andpembrolizumab or the anti-PDL1 antibody atezolizumab or an anti-CTLA-4antibody selected from the group consisting of ipilimumab andtremilimumab. 121. A use, method, antibody, nucleic acid, vector, hostcell or pharmaceutical composition as described herein in thedescription, examples and/or figures.

REFERENCES

In the text above, reference is made to the following publications, thecontents of which are hereby incorporated by reference.

-   1. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W.,    Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf,    D., Hassel, J. C., et al. 2010. Improved survival with ipilimumab in    patients with metastatic melanoma. N Engl J Med 363:711-723.-   2. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N.,    Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D.,    Sosman, J. A., Atkins, M. B., et al. 2012. Safety, activity, and    immune correlates of anti-PD-1 antibody in cancer. N Engl J Med    366:2443-2454.-   3. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J.,    Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J.,    Odunsi, K., et al. 2012. Safety and activity of antiPD-L1 antibody    in patients with advanced cancer. N Engl J Med 366:2455-2465.-   4. Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B.,    Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L.    L., et al. 2011. CD40 agonists alter tumor stroma and show efficacy    against pancreatic carcinoma in mice and humans. Science    331:1612-1616.-   5. Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A.,    Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H.,    Wolchok, J. D., et al. 2013. Fc-dependent depletion of    tumor-infiltrating regulatory T cells co-defines the efficacy of    anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695-1710.-   6. Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg,    S., Knee, D. A., Wilson, N. S., Dranoff, G., and    Brogdon, J. L. 2013. Activating Fc gamma receptors contribute to the    antitumor activities of immunoregulatory receptor-targeting    antibodies. J Exp Med 210:1685-1693.-   7. Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R.    C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J.,    et al. 2013. Depleting tumor-specific Tregs at a single site    eradicates disseminated tumors. J Clin Invest 123:2447-2463.-   8. White, A. L., Chan, H. T., French, R. R., Beers, S. A., Cragg, M.    S., Johnson, P. W., and Glennie, M. J. 2013. FcgammaRlotalotaB    controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol    Immunother 62:941-948.-   9. Li, F., and Ravetch, J. V. 2013. Antitumor activities of    agonistic anti-TNFR antibodies require differential FcgammaRlIB    coengagement in vivo. Proc Natl Acad Sci USA 110:19501-19506.-   10. White, A. L., Beers, S. A., and Cragg, M. S. 2014. FcgammaRIIB    as a key determinant of agonistic antibody efficacy. Curr Top    Microbiol Immunol 382:355-372.-   11. Middendorp, S., Xiao, Y., Song, J. Y., Peperzak, V., Krijger, P.    H., Jacobs, H., and Borst, J. 2009. Mice deficient for CD137 ligand    are predisposed to develop germinal center-derived B-cell lymphoma.    Blood 114:2280-2289.-   12. Snell, L. M., Lin, G. H., McPherson, A. J., Moraes, T. J., and    Watts, T. H. 2011. T-cell intrinsic effects of GITR and 4-1 BB    during viral infection and cancer immunotherapy. Immunol Rev    244:197-217.-   13. Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A.,    Sanmamed, M. F., and Wolchok, J. D. 2013. Agonist antibodies to TNFR    molecules that costimulate T and NK cells. Clin Cancer Res    19:1044-1053.-   14. McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A.,    Shevach, E. M., Collins, M., and Byrne, M. C. 2002. CD4(+)CD25(+)    immunoregulatory T cells: gene expression analysis reveals a    functional role for the glucocorticoid-induced TNF receptor.    Immunity 16:311-323.-   15. Marson, A., Kretschmer, K., Frampton, G. M., Jacobsen, E. S.,    Polansky, J. K., MacIsaac, K. D., Levine, S. S., Fraenkel, E., von    Boehmer, H., and Young, R. A. 2007. Foxp3 occupancy and regulation    of key target genes during T-cell stimulation. Nature 445:931-935.-   16. Taraban, V. Y., Rowley, T. F., O'Brien, L., Chan, H. T.,    Haswell, L. E., Green, M. H., Tutt, A. L., Glennie, M. J., and    Al-Shamkhani, A. 2002. Expression and costimulatory effects of the    TNF receptor superfamily members CD134 (OX40) and CD137 (4-1 BB),    and their role in the generation of anti-tumor immune responses. Eur    J Immunol 32:3617-3627.-   17. Beers, S. A., Chan, C. H., James, S., French, R. R.,    Attfield, K. E., Brennan, C. M., Ahuja, A., Shlomchik, M. J.,    Cragg, M. S., and Glennie, M. J. 2008. Type II (tositumomab)    anti-CD20 monoclonal antibody out performs type I (rituximab-like)    reagents in B-cell depletion regardless of complement activation.    Blood 112:4170-4177.-   18. White, A. L., Chan, H. T., Roghanian, A., French, R. R.,    Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J.    S., Al-Shamkhani, A., et al. 2011. Interaction with FcgammaRIIB is    critical for the agonistic activity of anti-CD40 monoclonal    antibody. J Immunol 187:1754-1763.-   19. White, A. L., Dou, L., Chan, H. T., Field, V. L., Mockridge, C.    I., Moss, K., Williams, E. L., Booth, S. G., French, R. R.,    Potter, E. A., et al. 2014. Fcgamma receptor dependency of agonistic    CD40 antibody in lymphoma therapy can be overcome through antibody    multimerization. J Immunol 193:1828-1835.-   20. Nimmerjahn, F., and Ravetch, J. V. 2005. Divergent    immunoglobulin g subclass activity through selective Fc receptor    binding. Science 310:1510-1512.-   21. Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S.,    Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. 2011.    An Fcgamma receptor-dependent mechanism drives antibody-mediated    target-receptor signaling in cancer cells. Cancer Cell 19:101-113.-   22. Haynes, N. M., Hawkins, E. D., Li, M., McLaughlin, N. M.,    Hammerling, G. J., Schwendener, R., Winoto, A., Wensky, A., Yagita,    H., Takeda, K., et al. 2010. CD11c+ dendritic cells and B cells    contribute to the tumoricidal activity of anti-DR5 antibody therapy    in established tumors. J Immunol 185:532-541.-   23. Li, F., and Ravetch, J. V. 2012. Apoptotic and antitumor    activity of death receptor antibodies require inhibitory Fcgamma    receptor engagement. Proc Natl Acad Sci USA 109:10966-10971.-   24. Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T.,    Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., and    Hattori, K. 2013. Engineered antibody Fc variant with selectively    enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and    FcgammaRlIa(H131). Protein Eng Des Sel 26:589-598.-   25. White, A. L., Chan, H. T., French, R. R., Willoughby, J.,    Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G.,    Dodhy, A., Polak, M. E., et al. 2015. Conformation of the human    immunoglobulin g2 hinge imparts superagonistic properties to    immunostimulatory anticancer antibodies. Cancer Cell 27:138-148.-   26. Gavin, M. A., Clarke, S. R., Negrou, E., Gallegos, A., and    Rudensky, A. 2002. Homeostasis and anergy of CD4(+)CD25(+)    suppressor T cells in vivo. Nat Immunol 3:33-41.-   27. Elpek, K. G., Yolcu, E. S., Franke, D. D., Lacelle, C.,    Schabowsky, R. H., and Shirwan, H. 2007. Ex vivo expansion of    CD4+CD25+ FoxP3+T regulatory cells based on synergy between IL-2 and    4-1 BB signaling. J Immunol 179:7295-7304.-   28. Zheng, G., Wang, B., and Chen, A. 2004. The 4-1 BB costimulation    augments the proliferation of CD4+CD25+ regulatory T cells. J    Immunol 173:2428-2434.-   29. Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M.,    Putintseva, E. V., Chudakov, D. M., and Rudensky, A. Y. 2016.    Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.    Immunity 45:1122-1134.-   30. De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani,    V., Politano, C., Bonnal, R. J., Provasi, E., Sarnicola, M. L.,    Panzeri, I., et al. 2016. Transcriptional Landscape of Human Tissue    Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory    Cells. Immunity 45:1135-1147.-   31. Tipton, T. R., Mockridge, C. I., French, R. R., Tutt, A. L.,    Cragg, M. S., and Beers, S. A. 2015. Anti-mouse FcgammaRlV antibody    9E9 also blocks FcgammaRIII in vivo. Blood 126:2643-2645.-   32. Li, F., and Ravetch, J. V. 2011. Inhibitory Fcgamma receptor    engagement drives adjuvant and anti-tumor activities of agonistic    CD40 antibodies. Science 333:1030-1034.-   33. Li, F., and Ravetch, J. V. 2012. A general requirement for    FcgammaRIIB coengagement of agonistic anti-TNFR antibodies. Cell    Cycle 11:3343-3344.-   34. Minard-Colin, V., Xiu, Y., Poe, J. C., Horikawa, M., Magro, C.    M., Hamaguchi, Y., Haas, K. M., and Tedder, T. F. 2008. Lymphoma    depletion during CD20 immunotherapy in mice is mediated by    macrophage FcgammaRl, FcgammaRlll, and FcgammaRlV. Blood    112:1205-1213.-   35. Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S.,    Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et    al. 2014. PD-1 identifies the patient-specific CD8(+) tumor-reactive    repertoire infiltrating human tumors. J Clin Invest 124:2246-2259.-   36. Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E.,    Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T.,    Fox, B. A., et al. 2013. OX40 is a potent immune-stimulating target    in late-stage cancer patients. Cancer Res 73:7189-7198.-   37. Sharma, P., Wagner, K., Wolchok, J. D., and Allison, J. P. 2011.    Novel cancer immunotherapy agents with survival benefit: recent    successes and next steps. Nat Rev Cancer 11:805-812.-   38. Segal, N. H., Gopal, A. K., Bhatia, S., Kohrt, H., Levy, R.,    Pishvaian, M. J., Houot, R., Bartlett, N., Nghiem, N.,    Kronenberg, S. A., et al. 2014. A phase 1 study of PF05082566    (anti-4-1 BB) in patients with advanced cancer. J Clin Oncol    32:suppl; abstr 3007.-   39. Molckovsky, A., and Siu, L. L. 2008. First-in-class,    first-in-human phase I results of targeted agents: highlights of the    2008 American society of clinical oncology meeting. J Hematol Oncol    1:20.-   40. Furness, A. J., Vargas, F. A., Peggs, K. S., and    Quezada, S. A. 2014. Impact of tumour microenvironment and Fc    receptors on the activity of immunomodulatory antibodies. Trends    Immunol 35:290-298.-   41. Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S.    D., and Reisfeld, R. A.

1997. Targeted interleukin-2 therapy for spontaneous neuroblastomametastases to bone marrow. J Natl Cancer Inst 89:1586-1594.

-   42. Curran, M. A., and Allison, J. P. 2009. Tumor vaccines    expressing flt3 ligand synergize with ctla-4 blockade to reject    preimplanted tumors. Cancer Res 69:7747-7755.-   43. Moore M W, Carbone F R, and Bevan M J. Introduction of soluble    protein into the class I pathway of antigen processing and    presentation. Cell. 1988; 54(6):777-85.-   44. French, R. R., Chan, H. T., Tutt, A. L., and    Glennie, M. J. 1999. CD40 antibody evokes a cytotoxic T-cell    response that eradicates lymphoma and bypasses T-cell help. Nat Med    5:548-553.-   45. Beers, S. A., French, R. R., Chan, H. T., Lim, S. H.,    Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim,    H., Cox, K. L., et al. 2010. Antigenic modulation limits the    efficacy of anti-CD20 antibodies: implications for antibody    selection. Blood 115:5191-5201.-   46. Lim, S. H., Vaughan, A. T., Ashton-Key, M., Williams, E. L.,    Dixon, S. V., Chan, H. T., Beers, S. A., French, R. R., Cox, K. L.,    Davies, A. J., et al. 2011. Fc gamma receptor IIb on target B cells    promotes rituximab internalization and reduces clinical efficacy.    Blood 118:2530-2540.-   47. Buchan, S. L., and Al-Shamkhani, A. 2012. Distinct motifs in the    intracellular domain of human CD30 differentially activate canonical    and alternative transcription factor NF-kappaB signaling. PLoS One    7:e45244.-   48. Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A., and    Allison, J. P. 2011. Combination CTLA-4 blockade and 4-1 BB    activation enhances tumor rejection by increasing T-cell    infiltration, proliferation, and cytokine production. PLoS One    6:e19499.-   49. Dahan R, Barnhart B C, Li F, Yamniuk A P, Korman A J, Ravetch    J V. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal    Antibodies Requires Selective FcγR Engagement. Cancer Cell. 2016    Jun. 13; 29(6):820-31. doi: 10.1016/j.ccell.2016.05.001. Epub 2016    Jun. 2. PMID: 27265505.-   50. Arce Vargas F, Furness A J S, Solomon I, Joshi K, Mekkaoui L,    Lesko M H, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben    Aissa A, Franz D, Werner Sunderland M, Wong Y N S, Henry J Y,    O'Brien T, Nicol D, Challacombe B, Beers S A; Melanoma TRACERx    Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium,    Turajlic S, Gore M, Larkin J, Swanton C, Chester K A, Pule M,    Ravetch J V, Marafioti T, Peggs K S, Quezada S A. Fc-Optimized    Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and    Synergizes with PD-1 Blockade to Eradicate Established Tumors.    Immunity. 2017 Apr. 18; 46(4):577-586. doi:    10.1016/j.immuni.2017.03.013. Epub 2017 Apr. 11. PMID: 28410988-   51. Römer PS1, Berr S, Avota E, Na S Y, Battaglia M, ten Berge I,    Einsele H, Hunig T.; Preculture of PBMCs at high cell density    increases sensitivity of T-cell responses, revealing cytokine    release by CD28 superagonist TGN1412. Blood. 2011 Dec. 22;    118(26):6772-82. doi: 10.1182/blood-2010-12-319780. Epub 2011 Sep.    19.

1. A method of treating cancer wherein a Treg depleting antibodymolecule is administered sequentially with an immunostimulatory antibodymolecule with the Treg depleting antibody molecule being administeredprior to administration of the immunostimulatory antibody molecule.
 2. Amethod according to claim 1, wherein said immunostimulatory antibodymolecule is a CD8 activating and/or CD8 boosting antibody molecule.
 3. Amethod according to claim 1, wherein the cancer is a solid tumour, suchas a solid tumour selected from the group consisting of sarcomas,carcinomas, lymphomas and ovarian cancer and/or a solid tumour selectedfrom the group consisting of squamous cell carcinoma (SCC), thymoma,neuroblastoma or ovarian cancer.
 4. A method according to claim 1,wherein said Treg depleting antibody molecule and/or saidimmunostimulatory antibody molecule is selected from the groupconsisting of a full-size antibody, a Fab, a Fv, an scFv, a Fab′, and a(Fab′)₂.
 5. A method according to claim 1, wherein said Treg depletingantibody molecule is a human IgG1 antibody, which optionally may beengineered for improved binding to at least one activatory FcγR.
 6. Amethod according to claim 1, wherein said Treg depleting antibodymolecule is selected from antibody molecules binding specifically to atarget belonging to the tumour necrosis factor receptor superfamily(TNFRSF).
 7. A method according to claim 6, wherein said Treg depletingantibody molecule is an antibody molecule that binds specifically to atarget selected from the group consisting of 4-1BB, OX40, and TNFR2. 8.A method according to claim 1, wherein said Treg depleting antibodymolecule is an antibody molecule that binds specifically to a targetselected from GITR, ICOS, CTLA-4, CD25 and neuropilin-1.
 9. A methodaccording to claim 7, wherein said Treg depleting antibody molecule isan anti-4-1BB monoclonal antibody molecule.
 10. A method according toclaim 9, wherein the Treg depleting antibody molecule is selected fromthe group consisting of antibody molecules comprising 1-6 of the CDRsselected from SEQ. ID. NOs: 1-6; 1-6 of the CDRs selected from SEQ. ID.NOs: 9-14; 1-6 of the CDRs selected from SEQ. ID. NOs: 17-22; 1-6 of theCDRs selected from SEQ. ID. NOs: 25-30; 1-6 of the CDRs selected fromSEQ. ID. NOs: 33-38; 1-6 of the CDRs selected from SEQ. ID. NOs: 41-46;1-6 of the CDRs selected from SEQ. ID. NOs: 49-54; 1-6 of the CDRsselected from SEQ. ID. NOs: 57-62; 1-6 of the CDRs selected from SEQ.ID. NOs: 65-70; 1-6 of the CDRs selected from SEQ. ID. NOs: 153-158; and1-6 of the CDRs selected from SEQ. ID. NOs: 163-168.
 11. A methodaccording to claim 10, wherein the Treg depleting antibody molecule isselected from the group consisting of antibody molecules comprising avariable heavy chain selected from the group consisting of SEQ. ID. NOs:7, 15, 23, 31, 39, 47, 55, 63, 71, 159, and 169, and/or a variable lightchain selected from the group consisting of SEQ. ID. NOs: 8, 16, 24, 32,40, 48, 56, 64, 72, 160, and
 170. 12. A method according to claim 10,wherein the Treg depleting antibody molecule is selected from the groupconsisting of antibody molecule comprising SEQ. ID. NOs: 7 and 8; SEQ.ID. NOs: 15 and 16; SEQ. ID. NOs: 23 and 24; SEQ. ID. NOs: 31 and 32;SEQ. ID. NOs: 39 and 40; or SEQ. ID. NOs: 47 and 48; SEQ. ID. NOs: 55and 56; SEQ. ID. NOs: 63 and 64, SEQ. ID. NOs: 71 and 72; SEQ. ID. NOs:159-160; and SEQ. ID. NOs: 169-170.
 13. A method according to claim 7,wherein said Treg depleting antibody is a human anti-OX40 monoclonalantibody molecule.
 14. A method according to claim 13, wherein the Tregdepleting antibody molecule is selected from the group consisting ofantibody molecule comprising 1-6 of the CDRs selected from SEQ. ID. NOs:73-78; 1-6 of the CDRs selected from SEQ. ID. NOs: 81-86; 1-6 of theCDRs selected from SEQ. ID. NOs: 89-94; 1-6 of the CDRs selected fromSEQ. ID. NOs: 97-102; 1-6 of the CDRs selected from SEQ. ID. NOs:105-110; 1-6 of the CDRs selected from SEQ. ID. NOs: 113-118; 1-6 of theCDRs selected from SEQ. ID. NOs: 121-126; 1-6 of the CDRs selected fromSEQ. ID. NOs: 129-134; 1-6 of the CDRs selected from SEQ. ID. NOs:137-142; 1-6 of the CDRs selected from SEQ. ID. NOs: 145-150, and 1-6 ofthe CDRs selected from SEQ. ID. NOs: 171-176.
 15. A method according toclaim 14, wherein the Treg depleting antibody molecule is selected fromthe group consisting of antibody molecules comprising a variable heavychain selected from the group consisting of SEQ. ID. NOs: 79, 87, 95,103, 111, 119, 127, 135, 143, 151, and 177, and/or a variable lightchain selected from the group consisting of SEQ. ID. NOs: 80, 88, 96,104, 112, 120, 128, 136, 144, 152 and
 178. 16. A method according toclaim 1, wherein the immunostimulatory antibody molecule is a human IgG2antibody or a human IgG4 antibody molecule, which optionally may beengineered for enhanced binding to human FcγRIIB over activatory Fcgamma receptors.
 17. A method according to claim 16, wherein theimmunostimulatory antibody molecule is a human IgG2b antibody molecule,which optionally may be engineered for enhanced binding to human FcγRIIBover activatory Fc gamma receptors.
 18. A method according to claim 1,wherein the immunostimulatory antibody molecule is an antibody thatbinds specifically to a target selected from the group consisting of4-1BB, OX40, ICOS, GITR, CTLA-4, CD25, PD-1 and PDL1.
 19. A methodaccording to claim 18, wherein the immunostimulatory antibody moleculeis an anti-4-1BB antibody molecule.
 20. A method according to claim 19,wherein the immunostimulatory antibody molecule is selected from thegroup consisting of antibody molecules comprising 1-6 of the CDRsselected from SEQ. ID. NOs: 1-6; 1-6 of the CDRs selected from SEQ. ID.NOs: 9-14; 1-6 of the CDRs selected from SEQ. ID. NOs: 17-22; 1-6 of theCDRs selected from SEQ. ID. NOs: 25-30; 1-6 of the CDRs selected fromSEQ. ID. NOs: 33-38; 1-6 of the CDRs selected from SEQ. ID. NOs: 41-46;1-6 of the CDRs selected from SEQ. ID. NOs: 49-54; 1-6 of the CDRsselected from SEQ. ID. NOs: 57-62; 1-6 of the CDRs selected from SEQ.ID. NOs: 65-70; 1-6 of the CDRs selected from SEQ. ID. NOs: 153-158; and1-6 of the CDRs selected from SEQ. ID. NOs: 163-168.
 21. A methodaccording to claim 20, wherein the immunostimulatory antibody moleculeis selected from the group consisting of antibody molecules comprising avariable heavy chain selected from the group consisting of SEQ. ID. NOs:7, 15, 23, 31, 39, 47, 55, 63, 71, 159 and 169, and/or a variable lightchain selected from the group consisting of SEQ. ID. NOs: 8, 16, 24, 32,40, 48, 56, 64, 72, 160 and
 170. 22. A method according to claim 20,wherein immunostimulatory antibody molecule is selected from the groupconsisting of antibody molecule comprising SEQ. ID. NOs: 7 and 8; SEQ.ID. NOs: 15 and 16; SEQ. ID. NOs: 23 and 24; SEQ. ID. NOs: 31 and 32;SEQ. ID. NOs: 39 and 40; and SEQ. ID. NOs: 47 and 48; SEQ. ID. NOs: 55and 56; SEQ. ID. NOs: 63 and 64, SEQ. ID. NOs: 71 and 72, SEQ. ID. NOs:159 and 160, and SEQ. ID. NOs: 169 and
 170. 23. A method according toclaim 18, wherein the immunostimulatory antibody molecule is ananti-OX40 antibody molecule.
 24. A method according to claim 23 whereinthe immunostimulatory antibody molecule is selected from the groupconsisting of antibody molecule comprising 1-6 of the CDRs selected fromSEQ. ID. NOs: 73-78; 1-6 of the CDRs selected from SEQ. ID. NOs: 81-86;1-6 of the CDRs selected from SEQ. ID. NOs: 89-94; 1-6 of the CDRsselected from SEQ. ID. NOs: 97-102; 1-6 of the CDRs selected from SEQ.ID. NOs: 105-110; 1-6 of the CDRs selected from SEQ. ID. NOs: 113-118;1-6 of the CDRs selected from SEQ. ID. NOs: 121-126; 1-6 of the CDRsselected from SEQ. ID. NOs: 129-134; 1-6 of the CDRs selected from SEQ.ID. NOs: 137-142; 1-6 of the CDRs selected from SEQ. ID. NOs: 145-150;and 1-6 of the CDRs selected from SEQ. ID. NOs: 171-176.
 25. A methodaccording to claim 24, wherein the immunostimulatory antibody moleculeis selected from the group consisting of antibody molecules comprising avariable heavy chain selected from the group consisting of SEQ. ID. NOs:79, 87, 95, 103, 111, 119, 127, 135, 143, 151 and 177, and/or a variablelight chain selected from the group consisting of SEQ. ID. NOs: 80, 88,96, 104, 112, 120, 128, 136, 144, 152 and
 178. 26. A method according toclaim 24, wherein the immunostimulatory antibody molecule is selectedfrom the group consisting of antibody molecules comprising SEQ. ID. NOs:79 and 80; SEQ. ID. NOs: 87 and 88; SEQ. ID. NOs: 95 and 96; SEQ. ID.NOs: 103 and 104; SEQ. ID. NOs: 111 and 112; SEQ. ID. NOs: 119 and 120;SEQ. ID. NOs: 127 and 128; SEQ. ID. NOs: 135 and 136; SEQ. ID. NOs: 143and 144; SEQ. ID. NOs: 151 and 152; and SEQ. ID. NOs: 177-178.
 27. Amethod according to claim 18, wherein the immunostimulatory antibodymolecule is a human anti-PD1 monoclonal antibody molecule, a humananti-PDL1 monoclonal antibody molecule or a human anti-CTLA-4 monoclonalantibody molecule.
 28. A method according to claim 27, wherein thewherein the immunostimulatory antibody molecule is a human anti-PD1monoclonal antibody molecule selected from the group consisting ofnivolumab and pembrolizumab or the anti-PDL1 antibody atezolizumab or ananti-CTLA-4 antibody selected from the group consisting of ipilimumaband tremilimumab.
 29. An anti-4-1BB antibody molecule selected from thegroup consisting of antibody molecules comprising 1-6 of the CDRsselected from SEQ. ID. NOs: 1-6; 1-6 of the CDRs selected from SEQ. ID.NOs: 9-14; 1-6 of the CDRs selected from SEQ. ID. NOs: 17-22; 1-6 of theCDRs selected from SEQ. ID. NOs: 25-30; 1-6 of the CDRs selected fromSEQ. ID. NOs: 33-38; 1-6 of the CDRs selected from SEQ. ID. NOs: 41-46;1-6 of the CDRs selected from SEQ. ID. NOs: 49-54; 1-6 of the CDRsselected from SEQ. ID. NOs: 57-62; 1-6 of the CDRs selected from SEQ.ID. NOs: 65-70; 1-6 of the CDRs selected from SEQ. ID. NOs: 153-158; and1-6 of the CDRs selected from SEQ. ID. NOs: 163-168. 30-34. (canceled)35. An anti-OX40 antibody molecule selected from the group consisting ofantibody molecule comprising 1-6 of the CDRs selected from SEQ. ID. NOs:73-78; 1-6 of the CDRs selected from SEQ. ID. NOs: 81-86; 1-6 of theCDRs selected from SEQ. ID. NOs: 89-94; 1-6 of the CDRs selected fromSEQ. ID. NOs: 97-102; 1-6 of the CDRs selected from SEQ. ID. NOs:105-110; 1-6 of the CDRs selected from SEQ. ID. NOs: 113-118; 1-6 of theCDRs selected from SEQ. ID. NOs: 121-126; 1-6 of the CDRs selected fromSEQ. ID. NOs: 129-134; 1-6 of the CDRs selected from SEQ. ID. NOs:137-142; 1-6 of the CDRs selected from SEQ. ID. NOs: 145-150, and 1-6 ofthe CDRs selected from SEQ. ID. NOs: 171-176. 36-39. (canceled)
 40. Anisolated nucleic acid encoding an antibody according to claim
 29. 41-81.(canceled)
 82. An isolated nucleic acid encoding an antibody accordingto claim 35.